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ABSTRACT OF THE DISSERTATION
Development of in vitro Drug Screening Platforms Using Human Induced Pluripotent Stem CellDerived Cardiovascular Cells
by
Yosuke Kurokawa
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2017
Professor Steven George, Chair
Professor Jonathan Silva, Co-Chair

Drug-induced cardiotoxicity is a critical challenge in the development of new drugs. Since the
advent of human pluripotent stem cell-derived cardiomyocytes (CMs), researchers have explored
ways to utilize these cells for in vitro preclinical drug screening applications. One area of interest
is microphysiological systems (i.e. organ-on-a-chip), which aims to create more complex in vitro
models of human organ systems, thus improving drug response predictions. In this dissertation,
we investigated novel analysis methods and model platforms for detecting drug-induced
cardiotoxicity using human induced pluripotent stem cell (iPSC)-derived cardiovascular cells.
First, we utilized human iPSC-derived CMs (iPS-CMs) to establish optical methods of detecting
cardioactive compounds. We utilized optical flow to assess the iPS-CM contractions captured
using brightfield microscopy. The parameters were then analyzed using a machine learning
algorithm to determine the accuracy of detection that can be obtained by the model for a given
drug concentration. This result was compared to the analysis of the calcium transients measured
using a genetically encoded calcium indicator (GCaMP6). The brightfield contraction analysis
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matched the detection sensitivity of fluorescent calcium transient analysis, while also being able
to detect the effects of excitation-contraction decoupler (blebbistatin), which was not detected
using calcium transient analysis.
Second, we utilize iPS-CMs to model trastuzumab-related cardiotoxicity. Trastuzumab, a
monoclonal antibody against ErbB2 (Her2), is used to treat Her2+ breast cancer and has known
clinical cardiotoxicity. We demonstrated that an active ErbB2 signaling via binding of
neuregulin-1 (NRG-1) to ErbB4 is necessary to detect the cardiotoxic effects of trastuzumab.
Activation of ErbB2/4 pathway via NRG-1 is cardioprotective, and we also demonstrated that
heparin-binding epidermal growth factor-like growth factor (HB-EGF) similarly activates the
ErbB2/4 pathway. Finally, we established a co-culture platform of iPS-CMs and endothelial cells
(ECs), which recapitulated the physiological phenomenon of EC-secreted NRG-1 activating the
ErbB2/4 pathway on the CMs.
Third, we demonstrated the use of human iPSC-derived ECs (iPS-ECs) for creating 3dimensionial vascular networks inside microfluidic devices. The iPS-ECs were characterized for
EC markers and physiological functions. We utilized a CDH5-mCherry iPSC line to create iPSECs that expressed VE-cadherin fused to mCherry. The vascular networks formed by the iPSECs were patent and perfusable, retaining 70 kDa dextran within the lumen of the vessels. The
vasculature responded to small molecule inhibitors, showing increased vessel formation in
response to TGF-β inhibitor SB431542 and decreased vessel formation in response to multitargeted receptor tyrosine kinase inhibitor sunitinib.
Taken together, our findings advance the current understanding and utility of iPS-CMs for drug
screening applications, while establishing platforms for creating microphysiological systems that

x

incorporate iPS-EC co-culture. The use of iPSC-derived cells opens possibilities for diseasespecific and patient-specific drug screening applications in the future.
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Chapter 1: Background and Motivation
The development of new drugs has played a critical role in reducing disease-related mortality
and improving quality of life in the current era of modern medicine. However, a significant
problem has started to disrupt the pharmaceutical industry and its ability to continue producing
new drugs: the rising cost of drug development. Current estimates of drug development costs are
between $1.3 to $2.6 billion for a single drug to be approved by the US Food and Drugs
Administration (FDA).1,2 While some dispute the exact costs and reasoning,3 pharmaceutical
companies have used the figure to justify high drug prices as a necessity in order to fund the
research and development of future drugs.4 The exact effects that high drug prices have on the
US are difficult to gauge, but researchers agree that high drug prices have negative clinical and
socioeconomic impacts and must be properly addressed.4
The drug development process can be broadly broken down into the preclinical and clinical
phases. In most cases, the preclinical phase of drug development starts by identifying compounds
of interest using a target-based approach, where a molecular target for a specific disease is
preidentified.5 This process is performed in high-throughput fashion using in vitro assays that
test for target binding. These compounds then undergo optimization to improve sensitivity and
specificity to the target. The lead compounds are then tested for safety and efficacy using
appropriate in vitro models and in vivo animal models. The compound of interest then undergoes
the three phases of clinical trials, where the compound must demonstrate safety and efficacy
among a large patient population. Phase I clinical trial tests for safety, while Phase II and Phase
III must show both safety and efficacy in the patient population in order to gain FDA approval of
the new compound for public use.
1

There are many reasons for the rise in the cost of drug development (reviewed extensively in
Scannell et al.6). First, an FDA-approved treatment option already exists for most prevalent
diseases. For a new drug to enter the market, the drug must show improved efficacy (or equal
efficacy with improved safety) over the current standard to care, which is more challenging than
showing efficacy compared to the placebo control. Second, the regulatory standards for drug
safety has become more rigorous, especially in areas with existing treatment options that have
been deemed safe. Third, the target-based drug screening paradigm may overestimate the
understanding of the disease mechanism. A drug that binds to a single molecular target may not
have the predicted therapeutic effect once delivered to a human patient due to a lack of causal
link between the target and the disease. An emerging theory also adds that the widespread
practice of mergers and acquisitions in the pharmaceutical industry has reduced innovation due
to decrease in market competition.7
One potential path to reducing the drug development costs is to improve the predictive power of
the preclinical drug development program, especially in the area of in vitro models, so that drugs
that enter clinical trials have a higher rate of success. The success rate of clinical trials is low,
with more than 80% of Phase II clinical trials between 2009 and 2011 failing.8 Improvements in
the success rate of drugs that enter human clinical trials would dramatically reduce the cost of
drug development, as clinical trials account for an estimated 57% of the total drug development
costs.1 The lack of predictive power in in vitro models have been long recognized, mostly
attributed to the lack of physiological relevance of the in vitro model compared to the human
body.9 Stakeholders have taken note of this opportunity, investing research capital on methods to
improve the available preclinical drug screening tools. One such funding mechanism is the
National Institutes of Health (NIH) Microphysiological Systems Program which, in coordination
2

with the Defense Advanced Research Projects Agency (DARPA) and the FDA, aimed to develop
advanced in vitro platforms that can be utilized for improved preclinical drug screening.10 With
this goal in mind, my dissertation focuses on the development of novel platforms and analysis
tools to improve our preclinical drug screening capabilities. The research specifically focuses on
using cardiomyocytes and endothelial cells derived from human induced pluripotent stem cells
(iPSCs) for drug screening applications.
The dissertation contains 5 subsequent chapters. Chapter 2 reviews the current state of cardiac
microphysiological systems, with an emphasis on the roles of non-myocytes in the heart and
their significance in preclinical drug screening applications. Chapter 3 focuses on the use of
optical methods combined with machine learning as a novel analysis tool to aid in the
identification of cardioactive compounds. Chapter 4 examines the significance of neuregulin in
modeling trastuzumab-related cardiotoxicity using iPSC-derived cardiomyocytes (iPS-CMs).
Chapter 5 explores the use of iPSC-derived endothelial cells (iPS-ECs) in creating 3-dimensional
(3D) vascularized microphysiological systems. Finally, chapter 6 concludes the dissertation by
remarking on future advances that can significantly advance the current state of preclinical drug
screening.

3

Chapter 2: Tissue Engineering the Cardiac
Microenvironment: Multicellular Microphysiological
Systems for Drug Screening
2.1

Introduction

The heart, like most other organs, is a complex and heterocellular system that has evolved to
perform specific functions. The most critical function of the heart is to pump blood to the rest of
the body, which is necessary for the transport of oxygen and nutrients to maintain viability.
Dysregulation of the cardiovascular system is a major concern in modern society; while the
development of new drugs and therapies have helped alleviate this problem, cardiovascular
disease remains the leading cause of deaths worldwide.11 Compounding this problem is the
observation that some FDA approved drugs for cardiovascular disease as well as a host of other
diseases (e.g., diabetes, inflammation) have subsequently exhibited cardiotoxic side effects,
leading to the withdrawal of numerous drugs from the market.12 New anticancer drugs are among
those that have shown unexpected negative cardiac side effects, further prompting the need to
improve current methods to screen drugs for possible cardiotoxicity.13,14
The current standard for preclinical drug screening is animal models, primarily mouse and rat
models, which have failed to fully recapitulate the human heart’s response to drugs. Compared to
humans, mice show profound differences in beating rate (500-724 bpm compared to 60-90 bpm)
as well as electrophysiological properties (e.g. electrocardiogram duration, repolarization
currents, and ion channel expression levels).15 The hERG binding assay has been developed and
implemented to screen for drugs that cause hERG-mediated QT-prolongation, but this method
does not address any other ion channels involved in cardiomyocyte electrophysiology and fails to
capture drug-induced cardiotoxicity.16 The inability to predict human cardiac physiological
4

response to drugs has contributed to higher rates of failure in clinical trials, putting patients at
unnecessary risk and raising the overall cost of drug development. A potential solution to the
current limitations of screening for cardiac drug toxicity is to develop in vitro models of human
cardiac physiology, which could provide better predictive power of potential cardiac toxicity and
thus improve the efficiency of drug discovery.
While intriguing, developing in vitro human models of cardiac function is not without significant
challenges. Given the complex mechanisms involved in various pathophysiological conditions of
the heart, an appropriately complex model will be necessary to study such events.17 Nonetheless,
researchers have put forth significant effort toward creating microphysiological models of the
heart, focusing on creating biomimetic cardiac tissue that recapitulates some of the key electrical
and mechanical properties of the heart, and thus an accurate pharmacological response. Over the
past five years, significant targeted funding from the National Institutes of Health (NIH),
Defense Advanced Research Projects Agency (DARPA), and the US Food and Drug
Administration (FDA) has stimulated interest in engineering microphysiological systems of not
only the heart, but other physiological systems (e.g., gastrointestinal tract, brain, kidney) that will
also potentially improve drug efficacy and toxicity.10
This review will present the recent progress in creating microphysiological models of the heart,
with an emphasis on drug screening applications. Starting with an overview of cardiac anatomy,
we will explore tissue engineering strategies that consider the choice of cellular and extracellular
components, as well as how to integrate these components temporally and spatially to recover
the most important features of cardiac function. Finally, we will discuss the most significant
remaining hurdles, and the future outlook for ultimate success.

5

2.2 Anatomical Considerations
The heart consists of several distinct anatomical units.18 The four heart chambers and associated
valves control the flow of blood in a unidirectional fashion through the heart. The spiral
arrangement of ventricular cardiac muscle fibers allows coordinated force generation adequate to
pump blood to the rest of the body. Action potentials are generated at the sinoatrial node, and the
frequency is modulated by the nervous system. Recreating the complexities of an entire heart is
currently intractable – and would likely be cost-prohibitive and unnecessary for drug screening
applications. Instead, microphysiological models of the heart have targeted the myocardium, the
source of electrical propagation and force generation in the ventricle, as the minimal functional
unit that could model drug responses and disease states (Fig. 2.1). Cardiomyocytes comprise the
largest volume of space in the myocardium, and demonstrate a highly ordered structure that

Figure 2.1: The cardiac microenvironment. Microphysiological models of the heart have focused mostly
on recapitulating the structures within the myocardium. Within a single section of the myocardium
(approximately 100 μm), several important cell types are present (cardiomyocytes, endothelial cells,
fibroblasts) in a specific structural arrangement to actively modulate the microenvironment.

6

coordinates action potential propagation and force generation. Adjacent cardiomyocytes form
intercalated disks, whereby intercellular junctions promote synchronous contractions via
electrical coupling.19 Connexins, and specifically connexin-43 (Cx43), are the predominant gap
junction proteins found between cardiomyocytes and is often utilized as a marker of electrical
coupling. The myocardium requires these coordinated electrical and mechanical activities in
order to perform its function, and dysregulation can lead to pathological conditions such as reentry ventricular arrhythmia. Single cell cardiomyocytes cannot model many of these conditions
and has led to the development of more advanced models of the myocardium that better mimic
physiologically relevant cardiac tissue.

2.3

2D Models

Since the advent of human pluripotent stem cell-derived cardiomyocytes (hPSC-CM),
researchers have explored their potential use in drug screening.20,21 Cardiomyocyte
differentiation has significantly increased in efficiency and reproducibility within the last decade,
helping to develop an accessible source of human cardiomyocytes. As the simplest model, a 2D
monolayer of hPSC-CM has been used to establish the basic response to cardioactive drugs using
techniques such as patch clamping,22,23 microelectrode arrays (MEAs),24 calcium-sensitive
dyes,25 voltage-sensitive dyes,26 and impedance measurements.27,28 Using induced pluripotent
stem cell-derived cardiomyocytes (iPS-CM), researchers have also been able to recapitulate
genetically-linked disease phenotypes such as long QT syndrome, which has created the
possibility of patient-specific and disease-specific drug screening.24,29–31 The FDA has already
started to outline plans to incorporate the use of hPSC-CM for screening proarrhythmic drugs,
and the use of hPSC-CM will likely be integrated as a part of the preclinical drug screening
process in the near future.32
7

One of the significant drawbacks in using hPSC-CM is the immature or “fetal-like” phenotype of
the cells.33 The electrophysiological properties and force of contraction vary significantly from
adult cardiomyocytes, raising questions on the validity of the drug response observed using
hPSC-CM.21,34 While a 2D monolayer of hPSC-CM expresses most of the ion channels that are
of interest for drug screening,24 hPSC-CM change ion channel expression levels and develop
subcellular structures such as sarcoplasmic reticulum over long culture periods (~100 days).35–37
The concern over hPSC-CM immaturity has further contributed to the development of
microphysiological systems, as many strategies to mature hPSC-CM involve mimicking the
native cardiac microenvironment, as recently reviewed.38
One strategy to improve 2D culture is cellular alignment. Native cardiomyocytes are rod-like in
structure and strongly align in the direction of contraction.39 Cardiomyocytes grown in 2D do not
spontaneously organize in such a manner, and hPSC-CM display a disorganized, circular
morphology.35 Many techniques have been developed to induce alignment in cardiomyocytes in
2D. Micropatterned ECM causes cardiomyocytes to take on an anisotropic morphology, and
increased conduction velocity in the longitudinal direction attributed to the formation of
intercalated disks.40,41 Using cardiomyocytes grown on micropatterned thin films, Grosberg et
al.42 formed strips of aligned cardiomyocytes that deformed in the direction of alignment. The
deformation can then be used to calculate the stress produced during contraction. Both normal
and abnormal conditions of the heart have been explored using this platform.43–45 Topographical
cues such as nanogrooves, nanofibers, or shrink-induced wrinkles also induce cardiomyocyte
alignment.46–49 Aligned cardiomyocytes have been utilized to study physiological action
potential propagation and have also shown varied response to isoprenaline compared to nonaligned cardiomyocytes.50,51 While 2D models lack many of the physiological features of the
8

myocardium, they offer a simple, robust, and potentially useful in vitro platform for drug
screening and disease modeling.

2.4

3D Models

In order to more fully replicate normal physiology and anatomical structure, cells must be grown
in a 3D microenvironment.52 Advances in tissue engineering methods, particularly in the areas of
synthetic biomaterials and microfabrication, have provided unprecedented opportunities to
culture cells in 3D, leading to the growing interest in creating 3D microphysiological systems.
The use of 3D culture has resulted in improved drug screening capabilities in many systems such
as tumor and liver models.53–57 3D models can more accurately recapitulate physiological
features of an organ system compared to 2D, and these methods have been applied to creating
3D microphysiological cardiac tissues.
Most tissue engineering approaches make use of scaffolding materials to create a 3D structure,
including native ECM components and synthetic polymers. The earliest attempts to create 3D
cardiac tissue employed neonatal rat cardiomyocytes and resulted in synchronously contractile
constructs.58 Lee et al.59 used a catheter balloon to create a 3D cardiac organoid with pumping
capacity. Embedding hPSC-CM into 3D constructs also results in synchronously contractile
tissue, demonstrating formation of gap junctions and responsiveness to cardioactive drugs.60
However, much like 2D monolayer cultures, these tissues lack structural organization at the
mesoscopic level (Fig. 2.2), as cardiomyocytes randomly orient within the 3D matrix.
Researchers have since developed several techniques using mechanical and electrical stimuli to
induce structural alignment of 3D cardiac tissues.

9

Figure 2.2: 3D cardiac tissue derived from hPSC-CM. (A) Embedding cardiomyocytes in 3D scaffolds
result in disorganized structures, as the cardiomyocytes show random sarcomere orientation within the
tissue (red = α-sarcomeric actin, blue = DAPI). (B) Using Velcro as an anchor along the edges, the 3D
cardiac tissue displays mesoscopic organization and alignment (red = myosin heavy chain, green =
sarcomeric α-actinin, blue = DAPI). Adapted and reprinted and with permission from Elsevier.60,68

Eschenhagen et al.61 pioneered the use of load-bearing anchoring points to induce alignment of
cardiomyocytes embedded in a gel. Velcro was used to anchor two sides of a collagen gel, and
cellular compaction of the gel induced alignment of embryonic chick cardiomyocytes
perpendicular to the sides. The concept of load-bearing anchors have resulted in numerous
designs using various ECM compositions that have helped engineer aligned cardiac tissue that
range from a few hundred microns to several millimeters.62,63 The deflection of posts can be used
to calculate contractile force, and the ease of tissue formation make these platforms amenable to
high-throughput drug screening. While early works utilized animal-derived cardiomyocytes,
similar structures have been created using hPSC-CM.64–67 These cardiac tissues show advanced
electrophysiological properties (e.g. increased conduction velocity, intercalated disk formation)
and recapitulate many of the physiological contractile properties seen in vivo.68
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Electrical stimulation has also been utilized to induce alignment of cardiomyocytes. Using
electrical pulses that mimic that of the native myocardium, Radisic et al.69 created aligned
cardiac tissues that showed enhanced electrical and contractile properties. Using a platform
termed the “biowire”, electrical stimulation at a superphysiological rate induced advanced
electrophysiological maturation in cardiac tissues derived from hPSC-CM.70 Electrical
stimulation plays a significant role in the maturation of 3D cardiac tissues, and there is growing
evidence that providing electrical stimulation in combination with mechanical load or
stimulation can further mature these tissues.71,72
Researchers have also explored the use of scaffold-free 3D culture systems. Cardiomyocyte
differentiation protocols that employ embryoid bodies (EBs) result in contractile 3D constructs in
suspension.73 Due to the presence of non-myocytes in the differentiated EBs, most researchers
dissect and replate the cardiomyocytes onto 2D substrates; however, recent efforts have focused
on recreating cardiomyocyte spheroids that can be grown in suspension, making use of
techniques such as forced aggregation and hanging-drop culture.74,75 These scaffold-free systems
lack structural organization, but offer a synchronous, cell-dense tissue with the expected
response to adrenergic receptor agonists. These small aggregates can also be used as building
blocks to efficiently create larger scale tissues, which can potentially reduce the time of culture
necessary to form syncytium compared to enzymatically disaggregated cardiomyocytes.66,76
While these tissues initially lack cellular alignment, load-bearing anchors can be utilized to
create aligned, synchronous cardiac tissues. Singularized cardiomyocytes also self-aggregate in
suspension to form a cell-dense cardiac tissue. Mathur et al.77 recently reported the formation of
organized cardiac tissue by loading single-cell hPSC-CM in a microfabricated device, which
demonstrated a physiological response to cardioactive drugs.
11

2.5

Co-Culture Models

While researchers have succeeded in constructing cardiac tissues with advanced physiological
form and function, most of the work has used an incompletely-defined population of cells
obtained through cardiomyocyte differentiation. As cardiomyocyte differentiation efficiency
increases and new purification techniques develop, future studies may have the opportunity to
use a pure population of hPSC-CM.78–80 Interestingly, a pure population of cardiomyocytes is not
necessarily the desired starting point. Many other cell types exist within the heart, are abundant
in number, and play key roles in the physiological function of the myocardium.81 Early studies
have shown that the presence of non-cardiomyocytes help mature hPSC-CM compared to a pure
cardiomyocyte population.82 The inclusion of more than one cell type complicates the
methodology, but should result in more physiologically relevant models, making co-culture
systems a critical part of developing microphysiological models.83 While many functions of noncardiomyocytes in the heart have been elucidated in vivo, the role of co-culture systems in
creating physiologically relevant cardiac tissues remains largely unexplored. This section will
describe some of the early efforts in creating co-culture models of the heart, and explore the
significance of non-myocytes in microphysiological systems of the myocardium for drug
screening (summarized in Fig. 2.3).

2.5.1 Endothelial cells
Endothelial cells serve many critical functions in the heart. For example, endothelial cells line
the interior surfaces of the myocardium (the endocardium) and blood vessels, providing a barrier
function that controls communication between the myocardium and blood.18 A high density
capillary network also exists in the myocardium to meet the large metabolic requirements of the
contracting myocardium resulting in a very intimate association between cardiomyocytes and
12

Figure 2.3: The influence of non-cardiomyocytes and other factors present in the native cardiac
microenvironment. Using various modes of communication, cardiomyocyte functions are strongly
affected by the presence of endothelial cells, fibroblasts, and other cells and secreted factors. Many of the
responses that the cardiomyocytes undergo in the presence of these signals are closely tied to parameters
that are commonly used as a readout for detecting cardiotoxic effect, highlighting the significance of a
complex microphysiological model for capturing a more physiological response to drugs.

endothelial cells. In fact, every cardiomyocyte is no more than 2-3 µm from a microvascular
endothelial cell.84,85
In addition to their barrier function, endothelial cells extensively communicate with
cardiomyocytes in both developing and adult hearts.86 Many modes of interaction between
endothelial cells and cardiomyocytes have been discovered to play critical roles in
cardiomyocyte contractility and survival, and may be critical in developing microphysiological
systems that model cardiomyocyte response to drugs in vitro. Neuregulin-1 (NRG-1) is one of
several growth factors produced by cardiac endothelial cells.87 NRG-1 binds to the epidermal
growth factor receptor (EGFR) family of receptors, one of which is ErbB4, expressed by
ventricular cardiomyocytes. The binding of NRG-1 to ErbB4 and the signaling cascade through
13

heterodimerization of ErbB4 with ErbB2 is essential for early cardiac development, as knocking
out NRG-1, ErbB4, or ErbB2 in mice models results in developmental failure at embryonic day
10.5 with heart malformation.88–90 NRG-1 signaling has also been shown to improve
differentiation of hPSC towards a atrial/ventricular cardiomyocyte rather than a nodal cell, which
is generally desirable for recapitulating the myocardium.91 A recent study has also shown that the
addition of NRG-1β peptides induce maturation of mouse iPS-CM.92
The development of the drug trastuzumab (Herceptin®), a monoclonal antibody against human
ErbB2, helped formulate our understanding and clinical relevance of NRG-1 signaling.
Trastuzumab was developed as a chemotherapeutic drug that works by blocking ErbB2, which is
overexpressed in some tumor types (e.g. breast cancer), and showed improved efficacy when
combined with other chemotherapeutics such as anthracyclines (e.g., doxorubicin).93 Due to the
cardiotoxic nature of anthracyclines, combinatory chemotherapeutic treatment using trastuzumab
raised serious concerns regarding the off-target effects of blocking the NRG-1/ErbB signaling in
the heart.94 It was soon discovered that blocking ErbB2 in rat cardiomyocytes significantly
increased myofilament injury and contractile dysfunction caused by doxorubicin treatment.95
Many researchers have since confirmed the critical role of NRG-1/ErbB signaling in the adult
heart, including functions of growth, survival, proliferation, and repair of cardiomyocytes in both
homeostatic and maladaptive conditions.96–98
Human stem cell-derived cardiomyocytes express ErbB receptors, and the addition of NRG-1
influences the response to doxorubicin exposure as measured by cardiomyocyte impedance and
intracellular ATP.99 While the mechanism behind upregulation and downregulation of NRG-1
varies with different physiological and pathophysiological models, NRG-1 signaling from
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microvascular endothelial cells in the heart plays a critical role in cardiomyocyte response to
drug-induced cardiomyopathy.87,100
Several other paracrine factors are known to modulate cardiomyocyte function.84,86 Nitric oxide
(NO) released by endothelial cells not only controls vascular tone of blood vessels, but also
induces positive inotropic effects on cardiomyocytes.101 Importantly, endothelial-derived NO has
been shown to cause a change in cardiomyocyte contractile response to β-adrenergic stimulation,
signifying its importance in drug screening applications.102 NRG-1 signaling on cardiomyocytes
upregulates NO synthesis, further influencing cardiomyocyte contractility in the presence of
endothelial cells.103 Finally, endothelin-1 (ET-1) is another positive inotrope released by
endothelial cells.104 ET-1 also increases release of NO and NRG-1 from endothelial cells,
demonstrating the complex mechanisms involved in regulating cardiomyocyte functions.105,106
Most efforts surrounding endothelial-cardiomyocyte co-culture have centered on the goals of
creating vascularized cardiac tissue for cell therapy in repairing damaged myocardium.67,107,108
Transwells have been widely used to study the paracrine effects of endothelial-cardiomyocyte
co-culture; however, such systems are mostly limited to 2D monolayers. Additionally,
Transwells only capture the paracrine effects of the cells, while evidence exists that contactmediated signaling may be important for endothelial-cardiomyocyte communication.109 Using
3D scaffolds that are used in tissue engineering applications, future microphysiological systems
will look to scale down these tissues while maintaining the key effects of endothelialcardiomyocyte co-culture. Co-culturing hPSC-CM with endothelial cells and mesenchymal stem
cells improved the contractility and cardiac ion channel expression of the 3D cardiac tissue.110
Scaffold-free vascularized cardiac tissue can be created, but requires a tri-culture with stromal
cells in order to prevent endothelial cell death.111 Recent work by Vollert et al.112 successfully
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introduced an endothelial-coated channel through a 3D cardiac tissue. Endothelial co-culture has
proven to be valuable in other microphysiological organ systems,113,114 and we believe the same
will hold true for cardiac tissues.
The source and phenotype of the endothelial cells used in culture may also play an important role
in their function, as endothelial cells differ in function between different organs, but also within
different parts of the heart (e.g. microvascular, endocardial, aortic).115 For example, aortic
endothelial cells do not express NRG-1 and thus may result in a poor in vitro model when
predicting drug-induced cardiotoxicity.106 While human neonatal and adult endothelial cell
sources are readily available, the use of stem cell-derived endothelial cells is also a viable option
given the differentiation protocols that have been recently developed.116,117 Further
characterization may be necessary to assess the functional phenotypes of endothelial cells in the
context of the cardiac microenvironment.

2.5.2 Fibroblasts
Fibroblasts are commonly defined as mesenchymal cells that have an elongated morphology and
lack a basement membrane.118 While the exact numbers vary by species, cardiac fibroblasts
make up a significant portion of adult mammalian hearts in terms of total number of cells (45 to
70%), exceeding in number that of cardiomyocytes.118–121 Present throughout the heart,
fibroblasts occupy the connective tissue space between cardiomyocytes.121,122 Cardiac fibroblasts
play several key roles in cardiac development and physiology, including ECM remodeling,
paracrine signaling, mechanosensing, and electrical coupling.
Cardiac fibroblasts regulate ECM synthesis and degradation, which has been shown to be critical
for cardiomyocyte function. The cardiac ECM composition changes throughout development,
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and further changes in the ECM can be induced in many pathological conditions, as recently
reviewed.123 Collagens provide tensile strength within the heart, and is critical for hypertrophic
growth in the neonatal heart.124 Cardiac fibroblasts also produce periostin, which is highly
expressed in the developing heart, and has been shown to induce cardiomyocyte proliferation in
vitro and in vivo.125 Fibronectin, fibrillin, elastin, proteoglycans, and glycoproteins are also
present in the cardiac ECM, deposited mainly by cardiac fibroblasts.126,127 Fibroblasts also
secrete matrix metalloproteinases (MMPs) in order to remodel the cardiac ECM. The balance
between ECM proteins and MMPs is critical for ECM homeostasis, which can be affected by
external factors such as mechanical stimulation.118,128 A number of pathological conditions such
as myocardial infarction and pressure overload induce cardiac fibroblasts to undergo a
phenotypic change into myofibroblasts, increasing proliferation and deposition of collagen via a
TGFβ mediated pathway.120,126
Cardiac fibroblasts also directly couple with cardiomyocytes, utilizing connexins to allow
propagation of electrical signals.129 Fibroblasts are able to electrically couple cardiomyocytes
separated by up to 300 µm in distance in vitro, although there is considerable debate on the
extent of electrical coupling that occurs in vivo between fibroblasts and cardiomyocytes.130,131
Fibroblast-cardiomyocyte coupling significantly alters electrophysiological properties of
cardiomyocytes, affecting conduction speed, resting membrane potential, repolarization, and
excitability.132 The large number of cardiac fibroblasts in the SA node suggests that they also
modulate the function of nodal cells. In contrast, fibroblast-cardiomyocyte coupling in the
myocardium may be more pathological, and has been shown to induce abnormal depolarization
and reentry in vitro.133,134 Further studies must be performed to elucidate the exact role of
fibroblast-cardiomyocyte coupling in vivo, such that this function can be recapitulated in vitro.
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The role of including cardiac fibroblasts in cardiac microphysiological systems remains unclear.
Co-culture of cardiomyocytes with mouse-derived cardiac fibroblasts improved the contractility
of engineered cardiac tissues.135 Adding cardiomyocytes to pre-cultured, adherent fibroblasts and
endothelial cells results in improved cardiac tissue formation with elongated morphology and
increased electrical coupling via Cx43 expression.136,137 Studies have reported a population of
vimentin-positive cells that are dispersed in the periphery of 3D cardiac tissues created using
hPSC-CM, indicating that these fibroblast-like cells play a role in the formation of these
tissues.64,138 While increasing numbers of fibroblasts reduced electrophysiological maturation of
cardiac tissues, complete removal of non-myocytes led to decreased cell spreading and gel
compaction in 3D cardiac tissues.139 A recent study showed that adding 25% CD90+ cells to
hPSC-CM resulted in improved cardiac tissue formation and increased cardiomyocyte
maturation compared to cardiomyocyte only control.140
One of the challenges in using fibroblast co-culture models is the heterogeneity of fibroblasts
within the body, showing significant variation in function even within a single organ
system.127,131,141 Most researchers have used fibroblast sources that are not of cardiac origin,
which may be a concern for recapitulating the physiological microenvironment of the heart.
Identifying fibroblasts also poses a challenge; while anti-vimentin antibodies have been widely
used to label fibroblasts, endothelial cells also stain positively for such antibodies.142 Discoidin
domain receptor 2 (DDR2) has been established as a fibroblast marker, and may be useful for
future studies that incorporate cardiac fibroblasts in co-culture models.121

2.5.3 Non-cardiac cells and blood
Red blood cells (RBCs) account for the majority of cells present in blood, serving as oxygen
carriers to help deliver oxygen throughout the body. For tissue culture in vitro, most systems rely
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on diffusion of nutrients, including oxygen, using static exposure to cell culture medium. Due to
the low solubility of oxygen in medium lacking oxygen carriers, oxygen depletion is a serious
concern in microphysiological systems that employ 3D cardiac tissue, and may contribute to
abnormal tissue function.52 Perfusion of medium containing oxygen-carriers such as
perfluorocarbon can improve contractility of cardiac tissues cultured in vitro.143 Simple perfusion
of media also increases cell survival within 3D cardiac tissues compared to static controls.112,144
Implementation of other strategies to increase oxygen delivery such as vascularization may be
necessary to create and maintain cell-dense cardiac tissues.145,146 Nonetheless, it remains to be
seen whether implementation of such strategies are necessary for microphysiological systems,
whose size is at or near the limit of diffusion (~200-250 μm). The inclusion of vascular networks
may enable physiological delivery of drugs through blood vessels, which may facilitate our
understanding of pharmacokinetics (e.g. how readily drugs diffuse out of blood vessels) as well
as potential drug interaction with the endothelial lining of the vessel.
The choice of medium is significant, especially for co-culture systems where different cell types
require different nutrients and growth factors. While RPMI 1640 supplemented with B-27 is
commonly used to differentiate and maintain hPSC-CM, it is a very simple medium that may
lack important signaling molecules found in blood. The addition of serum in the media may
result in a more physiological media; however, the content of serum is undefined with inherent
batch to batch variability, and exposure to serum-containing media can alter hPSC-CM
phenotype and drug response to adrenergic receptor agonists.147 The determination of media
composition that promotes physiological behavior of cardiomyocytes grown in vitro will be an
essential step in improving the applicability of cardiac microphysiological systems for drug
screening.
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Finally, no co-culture model has successfully incorporated neuronal cells, which release
catecholamines and acetylcholine that directly regulate cardiomyocyte function.148,149 The
ventricles have high sympathetic innervation, and the release of catecholamines (e.g.
epinephrine, norepinephrine) result in positive inotropic and chronotropic effects.150 While the
physiological functions of these secreted factors in the heart are established, their significance in
creating cardiac microphysiological models remain unclear. Beauchamp et al.75 reported a
decrease in beating rate of cardiomyocyte spheroids over 30 days, while long-term stimulation
using phenylephrine (α-adrenergic receptor agonist) resulted in sustained beating rate over the
same period of time. Supplementation of phenylephrine and/or angiotensin-II have also been
shown to induce hypertrophic growth of cardiomyocytes both in 2D and 3D.151,152 Many other
factors found in blood may also improve tissue formation and maturation in vitro.153,154 For
example, the thyroid hormone tri-iodo-L-thyronine (T3) has been shown to induce maturation of
hPSC-CM 155–157.

2.6 Concluding Remarks and Future Outlook
Cardiac microphysiological models have made significant advancements over the last decade.
Through the use of hPSC-CM, we are closer to using human in vitro models of the heart as a tool
to augment drug screening assays. While it is not yet feasible to move away from animal models,
microphysiological systems offer a complementary platform to further improve detection of
drug-induced cardiotoxicity using human-derived cells. Many of the current models are
amenable to high-throughput screening and may soon be an integral part of the preclinical drug
screening process. The use of iPS-CM from patients who have genetic cardiac disorders can also
be utilized to recapitulate and develop treatment options for specific disease phenotypes. While
2D platforms are efficient and robust, technical difficulties, reproducibility, and physiological
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relevance are remaining challenges for the adaptation of 3D platforms for drug screening
applications. Without a method to standardize and compare drug responses across different drug
screening models, it is difficult to determine which platforms are the most relevant. Widelyapplicable functional readouts will need to be developed for validating drug responses obtained
using these microphysiological models.
Advances in tissue engineering have been critical in the development of cardiac
microphysiological systems. Using various strategies to control the cellular and extracellular
components of the tissue, researchers have successfully created relatively mature and functional
models of the myocardium. There is also an increasing interest in utilizing organogenesis
strategies to recreate the in vivo microenvironment, relying on pluripotent cells to self-assemble
and reconstruct both the structure and function of the organ or organ parts.158 With the
emergence of cardiac progenitor cells that can differentiate into various cell types that make up
the heart, it may be feasible to form cardiac organoids that recapitulate many of the features
found in the myocardium or even the whole heart. As more advanced microphysiological models
of the heart become a reality, the predictive power of these models in drug screening as well as
disease modeling applications will continue to develop.
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Chapter 3: Machine Learning Plus Optical Flow: A Simple
and Sensitive Method to Detect Cardioactive Drugs
3.1

Introduction

The current state of drug development is costly and inefficient: only 1 out of 5,000 compounds
available at the drug discovery stage will achieve Food & Drug Administration (FDA) approval,
and the process takes approximately 14 years at a cost of 1.5 billion U.S. dollars.159 A significant
portion of this cost is attributed to withdrawal of drugs in clinical phases or post-FDA approval,
30% of which is from cardiotoxicity.160 For example, the diuretic drug Cisapride’s undetected
cardiotoxic effects resulted in 175 deaths and 386 cases of serious ventricular arrhythmia before
it was removed from the market in 2000.161
Clearly current preclinical screening methods do not adequately detect cardiotoxicity. The advent
of human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) creates the
possibility of a better in vitro model of the human myocardium for various applications including
drug screening.29,162,163 While current protocols result in iPS-CMs that are immature,33 they do
express several important phenotypic characteristics including key contractile and channel
proteins.23 However, a persistent challenge for developing a high-throughput drug screening
platform using iPS-CMs is the need for a simple and reliable method to measure key
electrophysiological and contractile properties.
Invasive methods, such as patch clamping, are traditionally limited to single cell analysis, and
have proven difficult for high-throughput applications. Attempts to incorporate patch-clamping
into high-throughput and commercial use are limited by cell membrane quality.164 In addition,
the instability of the seals prevents extended or longitudinal studies.165,166 Fluorescence-based
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optical methods such as voltage and calcium sensitive dyes provide non-invasive means to
observe electrophysiological properties of iPS-CMs.167 However, these dyes can impact cell
function, and therefore are not suitable for prolonged studies. Furthermore, both dyes and
genetically encoded indicators are subject to photobleaching effects.168,169 Microelectrode arrays
(MEA) have high-throughput capabilities, but require a cluster of CMs for accurate electrical
signals.24,170 Similarly, impedance-based measurements offer non-invasive, high-throughput
methods of drug screening, but are limited to monolayer cell cultures.171,172
Therefore, there remains a need to develop a high-throughput, sensitive, yet non-invasive
detection platform for iPS-CMs. We have previously demonstrated a platform that utilizes
brightfield images of iPS-CMs to measure drug effects on cardiac behavior (e.g. the positive
chronotropic effects of isoprenaline)51 Optical flow analysis is performed on the images to
generate vectors representative of cardiomyocyte motion. This inexpensive and non-invasive
imaging method requires only the use of a brightfield microscope and camera, and is thus
applicable to longitudinal studies in cell clusters, monolayers, and individual cells. To enhance
this methodology, our current study pairs the brightfield optical flow method with a
computational analysis method: supervised machine learning. Machine learning can evaluate
multiple parameters simultaneously without a priori knowledge; therefore, it can discover
unexpected relationships to potentially yield better detection. Furthermore, machine learning
provides a singular quantitative index that summarizes the impact of multiple parameters, and
thus simplifies the assessment of drug effects on cardiomyocytes. We hypothesize that
combining machine learning with optical flow detection will produce an automated, highthroughput methodology that is more sensitive than fluorescence-based detection schemes to
capture drug-induced effects on human iPS-CMs.
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To test our hypothesis, we evaluated the iPS-CMs response to three cardioactive drug
compounds with distinct, dissimilar effects: E-4031 (hERG K+ channel inhibitor), verapamil (Ltype Ca+ channel blocker), and blebbistatin (myosin-II inhibitor). The concentration range for
each drug was selected based on the demonstrated window of cardioactive effects in previous
studies.170 To the best of our knowledge, we report for the first time the integration of optical
flow with machine learning on iPS-CMs to detect drug induced cardioactive effects, and
demonstrate superior performance to fluorescence-based methods.

3.2

Materials and Methods

3.2.1 Cell culture
A human iPS cell line constitutively expressing the calcium sensitive fluorescent protein
GCaMP6 (WTC11-AAV-CAG-GCaMP6) was obtained from Dr. Bruce Conklin (Gladstone
Institute of Cardiovascular Research). The cells were grown on 6-well plates coated with
Matrigel (Corning) in mTeSR1 (Stem Cell Technologies) with daily media replacement. The
cells were passaged at 80% confluence using StemPro Accutase (Life Technologies) and seeded
on Matrigel-coated plates in mTeSR1 containing 10 µM Y-27632 (Tocris), a Rho-associated
protein kinase (ROCK) inhibitor. A small molecule Wnt modulatory protocol was used for
cardiomyocyte differentiation.173 In brief, the cells were seeded onto Matrigel-coated 12-well
plates at 100,000 cells/well, and the cells are grown for 3 days prior to differentiation. On Day 0,
the media was switched to RPMI 1640 (Life Technologies) and B-27 supplement without insulin
(RPMI/B-27-Ins, Life Technologies) containing 12 µM CHIR99021 (Selleckchem), a glycogen
synthase kinase 3 (GSK3) inhibitor. On Day 1, the media was replaced by RPMI/B-27-Ins. On
Day 3, the media was replaced by RPMI/B-27-Ins containing 5 µM IWP2 (Tocris), a Wnt
signaling inhibitor. On Day 5, the media was replaced by RPMI/B-27-Ins. On Day 7, the media
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was replaced by RPMI/B-27 followed by media replacement every 3 days. Spontaneously
contracting cells were observed between Day 10 to 13. After 20 days post-differentiation,
cardiomyocytes were purified using lactate selection.79 In brief, the cells are washed three times
using DPBS (Life Technologies), and the media was replaced by glucose-free DMEM (Life
Technologies) containing 4 mM lactic acid (Sigma-Aldrich) and 25 mM HEPES (Life
Technologies). The media was replaced every 2 days for 8 days, with gentle shaking to dislodge
dead cells.

3.2.2 Drug treatment
Cardiomyocytes were passaged by incubating in collagenase II (Life Technologies) for 1 hour
followed by TrypLE Select (Life Technologies) for 4 minutes. The cells were counted and
seeded as a dense monolayer on Matrigel-coated 8-chamber Lab-Tek II Chamber Slides
(Electron Microscopy Sciences) at 150,000 cells/well. The drugs E-4031, verapamil, and
blebbistatin (Sigma-Aldrich) were delivered in RPMI/B-27 at various concentrations known to
have cardioactive effects.170 Prior to exposure to drug compounds, three baseline measurements
were made at time points 0, 30, and 60 minutes. Drugs were serially added to the wells, waiting
20 minutes after addition before taking measurement. RPMI/B-27 was used as placebo. The drug
studies were performed on cardiomyocytes at 40+ days post-differentiation.

3.2.3 Time lapse imaging of cardiomyocyte motion
Images of contracting cardiomyocytes were acquired with an Olympus IX83 (Olympus) inverted
scope equipped with an ORCA-R2 color charge-coupled (Hamamatsu) camera and MetaMorph
software (Molecular Devices). To control for temperature and pH, an incubation system (model
ZILCS) consisting of a stage top incubator, temperature controller, and gas flowmeter (Tokai
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Hit) was used with 5% CO2. Both fluorescent and bright-field acquisitions were taken for
approximately 17.5 seconds at 15.6 fps at a resolution of 672 x 512 or at 8.6 fps at a resolution of
1392 x 1040 (subsequently downsized to a resolution of 672 x 512 via bilinear interpolation) and
saved as a TIFF stack. A script in MetaMorph was created to acquire the fluorescent image
automatically after the bright-field acquisition was completed. To address variation among cell
populations within the same sample, stage locations were recorded prior to any acquisitions to
ensure that the same cells among a sample were imaged.

3.2.4 Intracellular calcium from the GCaMP6 fluorescence
The TIFF stacks were imported to ImageJ (NIH), where a 240 by 240 pixels region of interest
(ROI) were selected for each stack. The average intensity value within the ROI for each frame
was measured and imported into MATLAB (MathWorks). An automated code was written to
identify the start and the peak of each contraction. An n-th order (n=2-10) polynomial fit was
used to normalize the decay of signal due to photobleaching. The data was used to calculate the
beating rate, peak amplitude, and CTD90. From this, the ratio of the CTD90 and the amplitude
was calculated, and defined as the shape ratio (SR90). The SR90 is relatively insensitive to
photobleaching (both numerator and denominator impacted equally), and was thus used to
correct for photobleaching of signal over time.

3.2.5 Optical flow & machine learning
Bright-field images were processed with an optical flow algorithm, as previously described, to
generate matrices of x- and y-directional vectors that represent cardiomyocyte motion, both
magnitude and direction.51,174 Using a custom MATLAB script, principal component analysis
(PCA) was used to summarize the magnitude and directionality of the vectors into a single
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variable. When this single variable is plotted over time, a contractile profile is generated. These
contractile profiles have distinct peaks that represent the contraction and relaxation. With the
contractile profiles, the user is prompted to identify the start of the first contraction for each
recording. By doing so, peaks with positive principal component analysis (PCA) values are
identified as the contraction phase and those with negative PCA values as the relaxation phase of
the cardiomyocyte beating motion. The software then calculates 12 parameters that describe the
overall shape of the contractile profiles (e.g. duration of the contraction phase) (Fig. A1.1). The
frequency parameter is defined as the inverse of the time (seconds) between the peak of the
contraction phase for a given beat and that of a subsequent beat. Based on this definition, the
frequency parameter cannot be calculated for the last beat acquired. Therefore any other
calculated parameters associated with the last beat are removed from the machine learning
portion.
Each of the cardiomyocyte contractions was then regarded as an individual sample for the
machine learning (ML) analysis. Support vector machine (SVM), a classifying ML algorithm,
was implemented to discern between normal and abnormal cardiomyocyte contractile profiles.
As most biological data do not have linear trends, a non-linear kernel, radial basis function, was
chosen for SVM. The classification between the contractions of the baseline measurements and
those of a given drug concentration was accomplished by randomly separating the data into a
training set and a test set. The data in the test set was withheld from the training process and only
used to evaluate the model. The two sets were formed by first randomly grouping one third of the
wells and the corresponding contractions of that drug condition into the test set. To ensure that
the test set has equal number of baseline and drug samples, the baseline measurements for one
ninth of the wells were randomly allocated for the test set. The reason is that the number of
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baseline measurements for each well outnumbered each drug condition of that corresponding
well three to one. The rest of the wells and respective contractions were used as the training set.
Within the training set, a 5-fold cross validation was performed to optimize the parameters for
the generated SVM model. The optimized SVM model was then used to classify the test set. The
SVM accuracy of the model was calculated by the ratio of correct classifications to the total
classifications for the test set. To account for potential sampling bias, this process was performed
50 times and the reported SVM accuracy was the average of all the runs. With this process
repeating numerous times and having random allocation each time for the test and training sets,
the size of each respective set varied from run to run. For the baseline measurements, each well
had approximately 9 contractions per video acquisition. With these numbers of contractions, the
training set used for the SVM classifier had at least 200 samples.

3.2.6 Statistical analysis
Statistical significance of GCaMP6 data was determined with a one-way repeated measure
ANOVA. A key assumption made in repeated measures ANOVA is the condition of sphericity,
the variance of the differences among all possible pairs of a group is equal. Sphericity was
determined using Maulchy's Test for Sphericity (p-value < 0.05). If the assumption of sphericity
was not correct, the Greenhouse-Geisser correction was used to adjust the reported p-values for
the one-way repeated measures ANOVA. If a significant p-value (p-value < 0.05) was obtained
from the Repeated-Measures ANOVA, we proceeded with Dunnett's test to determine which
concentration differed from our baseline measurements. Differences with p-values less than 0.05
were considered statistically significant. All reported values are in the format of mean±S.E.M.
All reported sample sizes (n) refer to independent wells of chamber slides (biological replicates).
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3.3

Results

3.3.1 Brightfield and fluorescence signal processing
For the brightfield analysis, optical flow was used to generate motion vectors representing iPSCM contractions (Fig. 3.1A). Using principal component analysis (PCA), we summarized these
motion vectors into a contractile profile that contains distinct peaks that represent the contraction
(positive PCA values) and relaxation (negative PCA values) as seen in Fig. 3.1B.
For this study, we chose Support Vector Machine (SVM) as the machine learning algorithm. In
SVM, a machine is trained with data to create an optimal model with generalizability. SVM
classifies the data points into two groups (e.g. normal and abnormal cardiomyocyte behavior) by
creating a decision boundary that separates the two groups. The model is evaluated by
classifying unseen or withheld data. This evaluation yields an accuracy value (SVM accuracy)
that reflects the effectiveness of the model. The percentage accuracy represents the ability to
identify an effect (e.g. 98% represents out of 100 samples, the machine can correctly classify 98
of the instances). In the absence of cardioactive compounds, we would expect the accuracy of the
machine learning to be random and therefore generate a SVM accuracy of approximately 50%.
Implementation of SVM is described in detail in the Methods.
As a fluorescence-based method, we utilized an iPS cell line transduced with a genetically
encoded fluorescent calcium indicator, GCaMP6 (Fig. 3.1C). This method is similar to those
found in industry for the high-throughput screening of drug-induced cardiotoxicity.20–22 In this
study, the raw GCaMP6 signal acquired over time shows a rapid decay due to photobleaching
(Fig. 3.1D). The photobleaching artifact was eliminated by fitting a polynomial curve to the
baseline of the signal, defined as the starting point of the calcium transient, and then normalizing
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Figure 3.1: Data acquisition and analysis for GCaMP6 and bright-field signal. (A) For the bright-field
method, images are processed by an optical flow algorithm to generate vectors that represent the motion
of the iPS-CMs. The blue vector arrows represent the average motion of 20 x 20 pixel regions, while the
red vector arrows represent 50 x 50 pixel regions. The convergence of the vector arrows toward a center
visually represents an iPS-CM cluster in the contraction phase. (B) Based on the vectors, a contractile
profile is derived from the 1st PCA of the norm of the x- and y-vectors. Positive PCA values indicate
contraction phase, while negative values signify the relaxation values. (C) GFP signal produced by the
contraction of cardiomyocytes derived from GCaMP6 iPS cells. (D) GCaMP6 signal recorded over time
for 3 sequential acquisitions at baseline. The signals show a rapid photobleaching effect within the first 5
seconds, but also show a photobleaching effect between the different acquisitions. (E) The starting points
and peaks of the calcium transients are identified using the detrended GCaMP6 signal. (F) A graphical
explanation of CTD90. The SR90 is defined as the ratio of CTD90 to the amplitude of a given calcium
transient. (G) A longitudinal experiment shows an artificial decrease in CTD90 due to photobleaching.
This is corrected by normalizing by the amplitude in SR90.
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the raw signal by the baseline value (Fig. 3.1E). In addition, the starting points were normalized
to zero using linear interpolation. From these data, we calculated the beating rate and the calcium
transient duration 90% (CTD90), defined as the duration of the fluorescent signal that was 90%
below the peak amplitude of the transient (Fig. 3.1F). CTD90 is described in detail in the
Methods.
In addition to the rapid photobleaching over a single acquisition time frame, we noted that the
GCaMP6 signal also experienced a smaller photobleaching effect over multiple acquisitions (Fig.
3.1G). This loss of signal intensity caused artificial decreases in CTD90; this was corrected by
normalizing CTD90 with the amplitude of the calcium transient signal. This corrected value is
referred to as the Shape Ratio 90 (SR90), and serves as one of the two parameters analyzed for
the GCaMP6 method (Fig. 3.1G). This effect was independent of time between acquisitions (Fig.
A1.2).

3.3.2 Control experiments
To ensure that the experimental setup (i.e. stage top incubator), time, and other external factors
do not significantly impact the behavior of iPS-CMs, a longitudinal experiment was performed.
iPS-CMs were recorded with both the CGaMP6 method and brightfield method for a total of 150
minutes at intervals of 30 minutes. In the analysis of the GCaMP6 signals, there were no changes
in the beating rate and SR90 (Fig. A1.3), indicating stability in the iPS-CM behavior during the
length of the experiment. For the brightfield method, the SVM classification was performed by
grouping the first three measurements (0, 30 and 60 minutes) as the baseline control in a similar
fashion to the GCaMP6 analysis. The baseline control was then compared to the 90, 120 and 150
minute time points. Corresponding SVM accuracies of 48.64±1.51, 48.22±1.57, and
49.67±1.41% were calculated (Fig. 3.2A), which are consistent with no longitudinal effect.
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Figure 3.2: Analysis of control experiments: longitudinal and placebo experiment. (A) In the longitudinal
experiment, behavior of iPS-CMs was monitored for an extended period of 150 minutes at 30 minute
intervals after baseline measurements. When the machine was tasked of classifying between the first and
last half of the timepoints, the SVM accuracies were approximately 50% as expected (n = 13). (B) To
ensure the drug delivery process had no effects on iPS-CMs, at each placebo condition, 10 μL of media
was added to the previous tested condition. The average SVM accuracy of all four placebo conditions was
50.42%, similar to that of the longitudinal experiments (n= 18). (C) Representative traces of the
contractile profile from the bright-field analysis show no differences among tested conditions.

The purpose of the placebo experiment was to evaluate the drug delivery process and serve as the
vehicle controls. In each placebo condition, 10 μL of RPMI/B-27 media, the vehicle for drug
treatment, was added to the iPS-CMs, for a total of four placebo deliveries. Analysis with the
GCaMP6 method indicated no change in beating rate and SR90 values when compared to the
three baseline measurements taken prior to the placebo treatments (Fig. A1.4). In the brightfield
method, the SVM accuracies were 48.75±1.01, 46.86±1.19, 50.40±0.98, and 55.67±1.03%
respectively for each of the placebo treatments (Fig. 3.2B), again consistent with no effect. Thus,
the drug delivery process had no significant impact on the behavior of iPS-CMs.

3.3.3 Response to E-4031
E-4031 is a known antiarrhythmic drug that blocks the human Ether-à-go-go-Related (hERG) K+
channel and subsequently prolongs the QT interval.23,24 The drug compound was administered to
the iPS-CMs at an increasing concentration of 1, 3, 5, 10 and 30 nM. E-4031 induces QT
prolongation, which was clearly seen in the contractile profiles generated from the brightfield
images (Fig. 3.3A). At the 10 nM condition, extension of the relaxation phase was seen,
32

Figure 3.3: Analysis of E-4031, a hERG K+ channel blocker known to prolong the QT interval. (A)
Representative traces of the contractile profile from the bright-field analysis show a pronounced
contraction elongation at the highest tested concentration (30 nM). (B) At the concentrations of 1, 3, and
5 nM, the SVM accuracies were approximately 50%, similar to those of the control experiments. For the
10 and 30 nM concentrations, the SVM accuracies increased to 79.82 + 0.77% and 83.55 + 1.08%
respectively. This increase among accuracies suggest the compound had a cardio-modulating effect on
the cells at those given concentrations (n = 15). (C) Using the GCaMP6 method, significant changes in
the beating rate were seen at the 30 nM concentration (p = 0.0175). (D) For the SR90 parameter,
significant differences were detected at the 10 and 30 nM concentration (p = 0.0355 and p < 10-4
respectively) (n = 15). * p < 0.05, *** p < 0.001

consistent with the inhibition of the hERG K+ channel that contributes to the rapid repolarization
of the cardiomyocytes. The lengthening of the relaxation phase became more evident and
dramatic at the next treatment level, 30 nM.
For the brightfield method, the SVM accuracies for concentration levels of 1 nM, 3 nM, and 5
nM (47.38±0.64, 50.45±1.05, and 49.19±1.49%) were similar to the baseline SVM accuracies
(48.84%) (Fig. 3.3B). At the 10 nM concentration, the SVM was able to attain an accuracy of
79.82±0.77%. The SVM accuracy continued to increase to 83.55±1.08% at 30 nM concentration.
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For the GCaMP6 method, a change in beating rate was detected only at 30 nM with a 6.38%
decrease (Fig. 3.3C). The SR90 increased by 10.73% and 21.51% for 10 nM and 30 nM
respectively (Fig. 3.3D), which were statistically different from baseline.

3.3.4 Response to verapamil
Verapamil is an L-type Ca2+ channel blocker that is used therapeutically to treat cardiac
arrhythmia.25,26 The drug compound was administered at increasing concentrations of 1, 10, 50,
and 100 nM. Verapamil causes QT shortening,27 which was consistent with the observed
decrease in the duration of the contractile profile, first seen at 10 nM(Fig. 3.4A). At 50 and 100

Figure 3.4: Analysis of verapamil, L-type Ca2+ channel blocker known to shorten QT duration. (A)
Representative traces of the contractile profile from the bright-field analysis show the QT shortening
effect begin at 10 nM and the negative inotropic effect at 50 nM. (B) At 1 nM, the SVM accuracy was
64.52 + 1.78%. At the 10, 50, and 100 nM concentrations, the SVM accuracies were all above 90%,
strongly indicating verapamil’s cardio-modulating effect. (n = 14). (C) In the GCaMP6 method,
significant changes were detected at the 50 and 100 nM concentrations (p < 10-4 and p < 10-4). (D)
Looking at SR90, significant differences were only detected at the 100 nM (p = 8.78 x 10-4) (n = 14). ***
p < 0.001
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nM, the shortening effect became more pronounced. In addition, the amplitude of the contractile
profiles significantly decreased, indicating a negative inotropic effect due to decreased levels of
intracellular calcium. In the brightfield method, the 1 nM concentration level had a SVM
accuracy value of 64.52±1.78% (Fig. 3.4B). At the 10 nM level, the generated SVM models
generated were able to achieve a SVM accuracy value that exceeded 90% (90.64±1.49%). The
SVM accuracy values continued to increase for the 50 nM and 100 nM concentration levels
(94.32±1.47 and 96.39±1.16% respectively). With the GCaMP6 method, the beating rate
decreased by 32.93% and 56.39% for 50 and 100 nM, respectively (Fig. 3.4C), which were
statistically significant. A change in the SR90 value, a 45.42% increase, was statistically
significant only at the highest concentration of 100 nM, (Fig. 3.4D).

3.3.5 Response to blebbistatin
Blebbistatin is a myosin-II inhibitor and a known excitation-contraction decoupler.28 The drug
compound was administered at an increasing concentration of 1, 10, 100, 500, and 1000 nM. The
SVM accuracy values for the 1 nM and 10 nM concentration levels were near 50% (44.02±1.45
and 47.38±1.44% respectively) (Fig. 3.5B). However, at 100 nM, the SVM accuracy increased to
85.08±1.49%. For both 500 and 1000 nM, SVM accuracy values increased to nearly 100%
(99.67±0.26 and 99.03±0.57% respectively). Conversely, in the GCaMP6 method, there were no
changes for any of the given concentrations (Fig. 3.5C, 3.5D).
As an excitation-contraction decoupler, blebbistatin induces a negative inotropic effect on the
iPS-CMs. The expected negative inotropic effects were seen starting at 100 nM (Fig. 3.5A). At
the highest concentration of 1000 nM, contraction and relaxation phases were still distinctly
seen. However, the max amplitude of the contraction peak for the 1000 nM concentration was
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Figure 3.5: Analysis of blebbistatin, a myosin-II inhibitor and excitation-contraction decoupler. (A)
Representative traces of the contractile profile from the bright-field method showed significant loss of
contractility at higher concentrations. (D) At 1 and 10 nM the SVM accuracies were near 50%,
suggesting minor to no changes in iPS-CMs. At 100 nM, the accuracy increased to 85.08 + 1.49%. For
500 and 1000 nM, the respective SVM accuracies further increased and were both near 100% (n = 11).
As expected with the GCaMP6 method, blebbistatin resulted in a false negative with no changes in (C)
beating rate or (D) SR90 at any of the tested concentrations (n = 11).

approximately 33-fold smaller than that of the baseline measurement (121.00 PCA value
compared 3976.42 PCA value).

3.4

Discussion

There is a pressing need for the development of new drug screening assays, as current methods
remain inadequate at detecting and predicting the cardiotoxicity of compounds. Leveraging the
capabilities of human stem cells to yield human cardiomyocytes, we present a simple and
inexpensive method that can identify drug-induced cardiac effects in iPS-CMs. The method pairs
brightfield imaging with optical flow and machine learning, and in all cases the method met or
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exceeded the sensitivity of a more traditional fluorescent-based intracellular calcium assay.
Thus, we believe our method has the potential to be used in high-throughput assays to identify
compounds with potential cardiotoxicity.
In conditions where no drug effects are anticipated (e.g. placebo experiments), the SVM
accuracy values were expected to be around 50%, reflecting the random chance of correctly
predicting the presence or absence of the drug or intervention. With successive addition of
compounds that are cardioactive, we would expect an increase in the SVM accuracy as the
decision boundary becomes more distinct. As a way to assess this method, iPS-CMs that are
genetically encoded with a calcium indicator, GCaMP6, were used as a control method due to its
similarities to multiple commercially available drug screening assays.
The average SVM accuracies obtained from the three longitudinal time points (90, 120, and 150
minutes) was 48.84%, and the average of all four placebo conditions was 50.42%. Furthermore,
the GCaMP6 data had no statistical significance in the recorded parameters among the conditions
in both these control experiments. These data suggests only small, but still negligible, variations
in iPS-CM behavior over time. Thus, both the longitudinal and placebo experiments confirmed
that when machine learning is applied to data of iPS-CMs in the absence of cardioactive
compounds, the SVM accuracy values would be in the range of 50%.
For the drug experiments, all three compounds were purposely selected for their known effect on
iPS-CM behavior. The compounds E-4031 and verapamil are known to have very strong
electrophysiological effects and only secondarily affect contractility. While calcium transients
are not a direct readout for cardiomyocyte electrophysiology, previous findings have shown that
changes in calcium transient are reliable surrogate readouts for changes in electrophysiology as
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they reflect changes in the excitation-contraction coupling.25,184,185 Assays that utilize calcium
transient measurements have been shown to specifically detect changes in human stem cellderived cardiomyocytes induced by E-4031 and verapamil.25,184 By demonstrating that the
brightfield method can capture the effects of these drugs (E-4031 and verapmil) that primarily
affect cardiomyocyte electrophysiology, we will have shown that the brightfield method is not
only effective to screen compounds that primarily affect contractility but is more broadly
applicable.
As expected, a more pronounced difference in iPS-CM behavior caused by increasing
concentrations of cardioactive compounds resulted in an increase in accuracy of the machine’s
prediction, as summarized in Table 1. Looking at E-4031, the SVM accuracy values remained
around 50% at the lower concentrations (1, 3, and 5 nM), indicating that there were no
cardioactive effects at the given concentrations. As higher concentrations were introduced,
noticeably higher SVM accuracy values were achieved (79.82% and 83.56% for 10 and 30 nM
respectively), suggesting drug-induced effects. These observations were corroborated by the
GCaMP6 data, which showed statistical significance among the parameters at 10 and 30 nM.

Table 3.1: Summary of the SVM accuracies calculated for the concentrations of each drug compound
with the bright-field method.
E-4031

Verapamil

Blebbistatin

Concentration

Accuracy

Concentration

Accuracy

Concentration

Accuracy

1 nM
3 nM
5 nM
10 nM
30 nM

47.38%
50.45%
49.19%
79.82%
83.55%

1 nM
10 nM
50 nM
100 nM

64.52%
90.64%
94.32%
96.38%

1 nM
10 nM
100 nM
500 nM
1000 nM

44.02%
47.38%
85.08%
99.63%
99.04%
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This separation in accuracy values highlights the utility and applicability of machine learning for
drug screening purposes.
Interestingly, at 10 nM of verapamil, a SVM accuracy of 90.64% was reported, indicating a
change in cardiomyocyte behavior, while the lowest concentration level that had a significant
change in the GCaMP6 data was at 50 nM. Verapamil inhibits the L-type Ca+ channel, thus
reducing both the amplitude and duration of the calcium transient. Thus, when normalizing by
the amplitude to calculate SR90, the decrease in CTD90 could be masked by the decrease in
amplitude. The shortened contractile profile (Fig. 3.4A) and decrease in CTD90, may suggest that
the effects of verapamil were masked at lower concentrations. If this is the case, the increases in
SR90 values at higher concentrations indicate that the relative decrease in the amplitude is greater
than the decrease in the duration of the calcium transient.
The SR90 parameter is prone to inaccuracies in drug compounds that elicit similar and
simultaneous changes in the amplitude and duration of calcium transients. However, it is
necessary as a means of normalization to counteract the photobleaching effect seen in the
GCaMP6 method. Attempts to normalize the decay to the control experiments were not possible
as the decay pattern among each sample of the longitudinal experiments greatly differed (Fig.
A1.2). Due to unpredictability of this decay, modeling the decreasing trend as linear or
exponential functions dependent on the acquisition number was unsuccessful as well. This
photobleaching effect is not unique to the GCaMP6 method, but rather present in most
fluorescence-based techniques. Although there are ways to minimize photobleaching effects,
there are considerable trade-offs. One method of adjustment is reducing the laser intensity;
however, this reduces signal-to-noise ratio and does not remove the photobleaching effect
altogether. A line-scan mode of acquisition can significantly reduce photobleaching, but this
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method eliminates wide field-of-view image acquisition, making it less suitable for highthroughput screening. The brightfield method is not subject to this photobleaching effect and can
be adapted for high–throughput, longitudinal studies on the same set of the iPS-CMs without
degradation of signals.
Blebbistatin, a myosin II inhibitor, was expected to have no changes in the GCaMP6 signal as
the inhibition occurs downstream in the proteins that generate the force of contraction, and not
intracellular calcium. The predictions of blebbistatin as a false negative in the GCaMP6 method
were confirmed as the analysis showed there were no differences in any of the tested
concentrations. However, in the brightfield method, a decrease in the amplitude of the contractile
profile was seen starting at 100 nM. This experiment clearly demonstrates that methods based on
the electrophysiological profiles, such as patch clamping, fluorescence-based optics, and MEA,
are prone to type II errors with drugs such as blebbistatin that decouple excitation and
contraction of iPS-CM. Thus, it is crucial in future cardiotoxicity drug screening assays to have a
component that monitors contraction and relaxation of the iPS-CMs.
The progression of the field towards including assays that monitor contractility is supported by
the number of commercially available systems that use impedance-based arrays.172,186–189
However, impedance-based arrays require a minimum number of iPS-CMs in a monolayer to
attain a signal. Because various culture techniques have been presented to acquire more
physiologically relevant iPS-CMs including multi-culture systems with fibroblasts and
endothelial cells, pacing, and culturing on 3-D platforms with anisotropic features, the
implementation of impedance-based arrays with such techniques is very difficult. 68–70,82,190,191 In
contrast, the brightfield method is simple as the only requirement is an optically clear platform
that allows real-time acquisition of brightfield images. The flexibility also allows this method to
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complement current techniques, such as intracellular calcium transients, to provide better
accuracy. Furthermore, this method is not limited to high-throughput drug screening purposes; it
can be easily employed for basic research use (e.g. as a readout in the study of iPS-CM
maturation).
The concept of using image-based analysis of cardiomyocyte beating dynamics has been
explored by various research groups.42,64,192 However, these studies have all required the need for
custom cell culture apparatuses. More recently, research groups have investigated brightfieldbased methods that are widely applicable to both standard cell culture apparatuses, such as a 384well cell culture plates, and custom ones.193–200 These respective methods have all demonstrated
the feasibility of tracking the contractile behavior of cardiomyocytes and extracting out
quantitative parameters to describe the apparent motion. Maddah et al. validated the
practicability of using brightfield microscopy to monitor contractile behavior of cardiomyocytes
in various setups: monolayer, cardiosphere and single cell.201 There are primarily two strategies
in achieving this: (i) methods that derive signals based on pixel differences or derivatives
between frames and (ii) methods that derive signals based on generated motion vectors.
In this study, the latter, a vector-based strategy using optical flow, was chosen as we have
previously demonstrated that the directional component of a vector can be crucial in the analysis
of cardiomyocyte motion.51 When looking at just the magnitude of pixel differences or vector
displacement, a contractile beat is assumed to be represented by two distinct peaks (one
representing the contraction phase and one representing relaxation).197,199 The ability to discern
between the two phases can be achieved if a resting phase is present. However, if the beating
frequency of the cells is increased, multiple phases can be embedded into one singular peak as
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we have shown in our previous study.51 Thus, methods that analyze both the magnitude and
directional components of vectors should provide more detailed information.
Admittedly, a potential limitation in this study’s set-up is the higher computational resource
requirement of the used the optical flow algorithm when compared to other algorithms used for
vector-based methods (e.g. block-matching and minimum quadratic difference
algorithms).195,198–200 However, the advantages of image segmentation and signal processing
using PCA along with machine learning analysis can be leveraged by applying these techniques
to the vectors of such other algorithms. The implementation of PCA summarizes the magnitude
and directional components of vectors into one dimensional data. It automatically discerns the
contraction phases (positive PCA values) from the relaxation phases (negative PCA values). In
addition, while not demonstrated in this study, the calculated spatial PCA can be applied to
segment asynchronously beating cell clusters. The SVM accuracy calculated in our method
serves as a singular quantitative index or metric that summarizes not only the impact of the 12
parameters, but also any underlying relationships or interactions among parameters. This index
becomes valuable for high-throughput screening of drug-induced cardiotoxicity by highlighting
compounds that have any cardioactive effect on the contractile behavior of cardiomyocytes.
In summary, we present a screening method that combines brightfield microscopy and machine
learning to enable the sensitive detection of changes in the contraction of human iPS-derived
cardiomyocytes. Unlike fluorescence-based methods that suffer from photobleaching, this
brightfield method does not result in the loss of signal over time even in longitudinal studies.
Furthermore, this approach can be implemented in combination with other screening methods,
and provides insights on how patterns in electrophysiological data are coupled to those of
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contraction. Moreover, this method is easily adaptable to various configurations, even 3D tissue
models, to enable easy, robust, and information-rich readouts of cardiomyocyte behavior.
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Chapter 4: Modeling Trastuzumab-Related Cardiotoxicity
in vitro Using Human Stem Cell-Derived Cardiomyocytes
4.1

Introduction

Cardiotoxicity screening using human pluripotent stem cell-derived cardiomyocytes (hPSCCMs) has rapidly evolved over the past decade. Initial efforts, including the Comprehensive in
vitro Proarrhythmia Assay (CiPA) initiative, have focused on using hPSC-CMs to determine the
arrhythmogenic potential of drugs, as several FDA-approved drugs have been pulled off the
market due to proarrhythmic side effects.202–204 While significant shortcomings still exist, hPSCCMs have proven to accurately detect clinically-relevant proarrhythmic cardiotoxicity for the
majority of compounds tested to date.23–25,170,187,205,206 Combined with the ability of induced
pluripotent stem cell-derived cardiomyocytes (iPS-CMs) to recapitulate patient-specific
phenotypes, novel drugs and therapeutics can be developed to target specific electrophysiological
disease states.207–209
More recently, researchers have explored the use of hPSC-CMs to better understand druginduced structural cardiotoxicity, defined as compounds that lead to decreased cardiomyocyte
viability.210–213 Given the wide use of anticancer drugs with known clinical cardiotoxicity
through loss of cardiomyocytes (e.g. anthracyclines such as doxorubicin),214 it is especially
important to have a human in vitro platform that can rapidly screen new compounds for potential
structural cardiotoxicity. Several recent studies have leveraged hPSC-CMs to develop a
mechanistic understanding of doxorubicin-induced cardiotoxicity.215–218
Separate from anthracyclines, the use of targeted drugs that inhibit specific pathways critical for
cancer progression have also gained broad clinical use.219 These compounds have led to
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improved clinical outcomes in certain cancer types; however, incidents of clinical cardiotoxicity
associated with these drugs have been reported.220,221 One such compound is trastuzumab
(Herceptin®), a monoclonal antibody against ErbB2 (Her2) used to treat patients with Her2+
breast cancer.93 Trastuzumab, administered with an anthracycline or on its own, significantly
increases the incidence of left ventricular dysfunction.93,94,222–224 Animal studies have shown that
ErbB2, together with its co-receptor ErbB4 and its activating ligand neuregulin-1 (NRG-1) are
critical for normal cardiac development and homeostasis.88–90,225 Studies using isolated rat
cardiomyocytes have shown that activation of the ErbB2/4 pathway with NRG-1 ameliorates
anthracycline-induced cardiotoxicity, suggesting a mechanism for trastuzumab’s cardiotoxic
effects.95,226
Here we utilize human iPS-CMs to model trastuzumab-related cardiotoxicity. We first
demonstrate that recombinant NRG-1 provides cardioprotective effects against anthracycline
exposure. We observe that ErbB2/4 signaling must be active in order to detect trastuzumabrelated cardiotoxicity. We additionally show that heparin-binding EGF-like growth factor (HBEGF) similarly activates the ErbB2/4 pathway and provides cardioprotection against
anthracyclines. We also demonstrate that a CM-EC co-culture platform enables the detection of
trastuzumab-related cardiotoxicity through the activation of the ErbB2/4 pathway via ECsecreted NRG-1. Our results demonstrate the potential of using hPSC-CMs to not only detect the
arrhythmogenic potential of drugs, but to also detect cardiomyocyte toxicity that impacts
viability.
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4.2

Materials and Methods

4.2.1 Cell culture
Wild-type human iPSCs reprogrammed from dermal fibroblasts of a healthy male volunteer (cell
line WTC-11) were cultured as previously described (gifted by Dr. Bruce Conklin, Gladstone
Institutes).227 The iPSCs express the calcium indicator GCaMP6f, which increases in fluorescent
intensity in response to increasing concentrations of Ca2+ in the cytosol.228,229 Routine checks for
mycoplasma were performed every 6 months using MycoAlert mycoplasma detection kit
(Lonza) following manufacturer’s protocol. The iPSCs were used between passages 40-60.
Endothelial colony forming cell-derived endothelial cells (ECFC-ECs) were isolated and
cultured in endothelial growth medium-2 (EGM-2, Lonza) as described previously.230 The
ECFC-ECs were used between passages 5-8.

4.2.2 Cardiomyocyte differentiation
A small molecule Wnt modulatory protocol was used as previously described, with
modifications231,232 (Fig. A2.1A). Briefly, iPSCs were grown to ~85% confluence on 6-well
plates coated with growth factor reduced Matrigel (Corning) in Essential 8 (E8) medium (Gibco).
On Day 0, the medium was changed to RPMI 1640 (Gibco) with B-27 supplement without
insulin (RPMI/B-27 -Ins, Gibco) containing 6 µM CHIR99021 (LC Laboratories). On Day 2, the
medium was changed to RPMI/B-27 -Ins. On Day 3, the medium was changed to RPMI/B-27 Ins containing 5 µM IWP2 (Tocris). On Day 5, the medium was changed to RPMI/B-27 -Ins. On
Day 7 and 10, the medium was changed to RPMI/B-27 (with insulin), with spontaneously
contracting cardiomyocytes appearing on Day 8. Non-cardiomyocytes were removed using
lactate selection,79 changing the medium every two days between Day 13 and 21 with RPMI
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1640 without glucose, with 4 mM lactic acid (Sigma-Aldrich), and 25 mM HEPES (Gibco). On
Day 24, the iPS-CMs were passaged by incubating in 200 U/ml collagenase II (GIbco) for 1 hour
followed by TrypLE Express (Gibco) for 4 minutes. The cells were either cryopreserved using
CryoStor10 (STEMCELL Technologies) or replated on Matrigel-coated 6-well plates.

4.2.3 Flow cytometry
The iPS-CMs were passaged between Day 27-30 and fixed in Fixation Buffer (BioLegend) for
20 minutes. The cells were permeabilized in PBS + 0.1% Triton-X (Sigma-Aldrich) and stained
using APC-preconjugated anti-cardiac troponin T (cTnT) antibody (Miltenyi Biotec) or a APCpreconjugated isotype control following manufacturer’s protocol. The samples were read using
the Guava easyCyte flow cytometer (Millipore) and analyzed using FlowJo.

4.2.4 Drug exposure
For all drug exposure studies, the iPS-CMs were passaged and replated on Matrigel-coated 96well plates at 50,000 cells/well. The targeted concentrations of doxorubicin (LC Laboratories),
NRG-1β (R&D Systems), HB-EGF (R&D Systems), trastuzumab (Genentech), and/or
corresponding volumes of vehicle control (Milli-Q ultrapure water) was added to the media as
specified. The drug exposure studies were performed using iPS-CMs between Day 30-40 of
differentiation.

4.2.5 Lactate dehydrogenase (LDH) measurement
After 72 hours of drug exposure, the LDH release was measured using the Pierce LDH
Cytotoxicity Assay Kit (Thermo Scientific) following manufacturer’s protocol. Absorbance was
measured using the Epoch microplate spectrophotometer (BioTek). For dose-dependent analysis,
measured absorbance values were calculated relative to the average of the no-drug control
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condition (Acontrol). For column analysis, the measured values were normalized to the
doxorubicin condition (ADOX) and baseline-subtracted the no-drug control condition using the
formula: normalized LDH release=(Ameasured-Acontrol)/(ADOX-Acontrol).

4.2.6 CM-EC co-culture
Both iPS-CMs and ECFC-ECs were passaged and mixed at the density to seed 40,000 and 2,500
iPS-CMs and ECFC-ECs per well, respectively, in a Matrigel-coated 96-well plate. The cells
were fed with EGM-2 for 3 days before drug exposure.

4.2.7 Quantitative real-time PCR
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) following manufacturer’s protocols,
and cDNA was produced using the High Capacity RNA-to-cDNA Kit (Applied Biosystems).
Gene expression was measured using Taqman Gene Expression Assays (NRG1:
Hs01101538_m1, HBEGF: Hs00181813_m1, 18S: Hs99999901_s1) using the CFX96 RealTime PCR Detection System (Bio-Rad). Relative expression was calculated using the
comparative Ct method,233 normalizing the expression level to the iPSCs.

4.2.8 Statistical analysis
All experiments were performed using at least 3 biological replicates per condition, and all
results are reported as mean±SD. Significance was calculated using either one-way analysis of
variance (ANOVA) in conjunction with Tukey’s multiple comparison test or two-way ANOVA
in conjunction with Dunnett’s or Holm-Sidak’s multiple comparison test, with p-values less than
0.05 considered statistically significant. Data were compiled, analyzed, and graphed using
Microsoft Excel and GraphPad Prism 6.
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4.3

Results

4.3.1 Differentiation and isolation of iPS-CMs
We differentiated the iPS-CMs using an established Wnt modulatory protocol, which was
followed by a metabolic selection whereby cardiomyocytes were enriched through their ability to
utilize lactate as an energy source. The resulting cell population stained positively for cTnT at
95.08±2.06% as measured by flow cytometry (Fig. A2.1B). A monolayer of iPS-CMs replated in
a 96-well plate and stained for cTnT demonstrated semi-organized troponin structures (Fig.
A2.1C), indicative of the immature phenotype of iPS-CMs.33,38

4.3.2 Cardioprotective effects of NRG-1
We hypothesized that active ErbB2/4 signaling is required to model trastuzumab-related
cardiotoxicity in vitro. Thus, we first studied the cardioprotective effects of NRG-1 via activation
of the ErbB2/4 pathway. Performing a dose-dependent response of iPS-CMs to doxorubicin with
or without NRG-1, we observed a statistically significant difference in the dose response curves
(F=23.73, p<0.0001) (Fig. 4.1A). The addition of NRG-1 provided cardioprotective effects,
reducing the LDH release by iPS-CMs and shifting the half-maximal effective concentration
(EC50) from 163.9 µM to 263.6 µM. The cardioprotective effects were most evident at the higher
concentrations of doxorubicin, with statistically significant differences between each point of the
curves above 10 µM doxorubicin concentration. Therefore, all subsequent studies utilized
doxorubicin concentration of 10 µM, which falls within the range of in vivo peak plasma
concentration of doxorubicin.215
Next, we observed that the cardioprotective effects of NRG-1 is dose-dependent, with
concentrations above 0.1 ng/ml causing a statistically significant reduction in LDH release in
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Figure 4.1: Cardioprotective effects of NRG-1. (A) A dose-response curve of doxorubicin with or
without the presence of NRG-1 as measured by relative LDH release. (-) indicates no doxorubicin.
*p<0.05, **p<0.005 between the control and +NRG-1 for the given doxorubicin concentration. (B) Doseresponse curve of NRG-1 with or without the presence of doxorubicin as measured by relative LDH
release. (-) indicates no NRG-1. *p<0.05, **p<0.005 compared to control condition with doxorubicin (no
NRG-1). Dox = doxorubicin.

response to doxorubicin (Fig. 4.1B). We also observed no significant changes in LDH release
following the addition of NRG-1 without doxorubicin exposure, suggesting that the
cardioprotective effects of NRG-1 is only detectable under cellular stress. Subsequent studies
utilized NRG-1 concentration of 1 ng/ml, which is in the range of average NRG-1 plasma
concentration.234

4.3.3 Trastuzumab-related cardiotoxicity
When iPS-CMs were exposed to varying concentrations of trastuzumab, no difference in LDH
release was observed with or without the addition of doxorubicin (Fig. 4.2A). Even in the
presence of NRG-1 (i.e. active ErbB2/4 signaling), the addition of trastuzumab did not lead to
any increased LDH release. However, in the presence of both NRG-1 and doxorubicin, it was
possible to detect the cardiotoxic effects of trastuzumab (Fig. 4.2B). While the addition of NRG1 resulted in a 56±14% decrease in normalized LDH release compared to doxorubicin alone, the
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Figure 4.2: Cardiotoxicity of trastuzumab. (A) A dose-response curve of trastuzumab with doxorubicin
or NRG-1 as measured by relative LDH release. None of these conditions detect trastuzumab-related
cardiotoxicity. (-) indicates no trastuzumab. (B) Trastuzumab (1 µM), combined with doxorubicin (10
µM) and NRG-1 (1 ng/ml), increases the normalized LDH release compared to having doxorubicin and
NRG-1 without trastuzumab. Adding trastuzumab and doxorubicin without the addition of NRG-1 does
not increase LDH release compared to having doxorubicin alone. **p<0.005. TZM = trastuzumab.

addition of both NRG-1 and trastuzumab led to a smaller (36±12%) decrease; in other words,
comparing the two conditions with both doxorubicin and NRG-1, the addition of trastuzumab led
to a 58±38% increase in normalized LDH release.

4.3.4 Cardioprotective effect of HB-EGF
Next, we explored whether we can observe a similar cardioprotective effect using HB-EGF,
another ligand that binds to ErbB4 and activates the ErbB2/4 pathway. Similar to NRG-1, we
observed a dose-dependent cardioprotective effect of HB-EGF against doxorubicin-induced
cardiotoxicity (Fig. 4.3A). We also did not observe a change in LDH release by the addition of
HB-EGF without the presence of doxorubicin. In the presence of HB-EGF, we also detected the
cardiotoxic effects of trastuzumab (Fig. 4.3B). The addition of HB-EGF resulted in a 26±19%
reduction in the normalized LDH release, but the addition of both HB-EGF and trastuzumab
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Figure 4.3: Cardioprotective effects of HB-EGF. (A) A
dose-response curve of HB-EGF with or without the
presence of HB-EGF as measured by relative LDH
release. (-) indicates no HB-EGF. **p<0.005 compared
to control condition with doxorubicin (no HB-EGF). (B)
The addition of HB-EGF (100 ng/ml) with doxorubicin
enables the detection of trastuzumab-related
cardiotoxicity as measured by increased normalized LDH
release. *p<0.05, **p<0.005. (C) No added
cardioprotective effects were detected by adding both
NRG-1 (1 ng/ml) and HB-EGF (100 ng/ml) compared to
NRG-1 alone as measured by normalized LDH release.
**p<0.005.

removed any statistically significant cardioprotective effects (decrease of 7.8±23%, p=0.6257).
Comparing the two conditions with both doxorubicin and HB-EGF, the addition of trastuzumab
resulted in a 27±24% increase in normalized LDH release.
Comparing the degree of cardioprotection provided by NRG-1 and HB-EGF, we observed that
NRG-1 significantly reduces the normalized LDH release compared to HB-EGF (Fig. 4.3C).
Importantly, the addition of both NRG-1 and HB-EGF does not provide any additional
cardioprotective effects compared to NRG-1 alone (56±14% vs. 63±5%, p=0.549).
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4.3.5 CM-EC co-culture platform
Since NRG-1 is mainly secreted by endothelial cells in the cardiac microenvironment,86 we
aimed to recapitulate this phenomenon using a co-culture of iPS-CMs and ECFC-ECs. First, we
measured that NRG-1 is expressed by the ECFC-ECs using qPCR and ELISA. Compared to
iPSCs and iPS-CMs, the ECFC-ECs have significantly higher NRG1 expression (Fig. 4.4A). The
secretion of NRG-1 into the growth medium was confirmed using ELISA, with protein
concentrations reaching 604±142 pg/ml in 48 hours. This level of NRG-1 is sufficient to observe
a significant cardioprotective effect based on the NRG-1 dose-response experiment (Fig. 4.1B).
In order to produce a simple and reproducible co-culture platform that is amenable to highthroughput analysis, we utilized a monolayer co-culture in 96-well plates. The iPS-CMs and
ECFC-ECs were seeded at a ratio of 16:1 (40,000:2,500) in order to promote even distribution of
the two cell types (Fig. 4.4B), whereas using higher concentrations of ECFC-ECs resulted in the

Figure 4.4: Co-culture of iPS-CM and ECFC-EC. (A) Relative expression of NRG1 between the iPSCs,
iPS-CMs, and ECFC-ECs. **p<0.005. (B) Representative image of the CM-EC co-culture. Green = iPSCM (GCaMP6), red = ECFC-EC (transduced). Scale bar = 250 µm. (C) The addition of trastuzumab with
doxorubicin increases normalized LDH release compared to doxorubicin alone. **p<0.005.
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overcrowding of ECFC-ECs (Fig. A2.2). Using this co-culture platform, we were able to detect
the cardiotoxic effects of trastuzumab. The addition of both doxorubicin and trastuzumab
increased the normalized LDH release by 10±12% compared to doxorubicin alone, which was
statistically significant (Fig. 4.4C). The addition of exogenous NRG-1 did not result in a reduced
LDH release, suggesting that the cardioprotective effects of ErbB2/4 signaling is already active
via EC-secreted NRG-1.

4.4

Discussion

Since the advent of hPSC-CMs, their potential use in drug screening applications has rapidly
expanded.235 In our study, we demonstrate that iPS-CMs are capable of detecting trastuzumabrelated cardiotoxicity when ErbB2/4 signaling is active, suggesting that trastuzumab is blocking
the cardioprotective effects of the ErbB2/4 pathway. While NRG-1 is recognized as the main
activator of the ErbB2/4 pathway in the cardiac microenvironment, we demonstrate that HBEGF can also activate the same cardioprotective pathway. Additionally, we demonstrate that a
co-culture platform of iPS-CMs and ECs recapitulates the physiological effects of EC-secreted
NRG-1 activating the ErbB2/4 pathway.
ErbB2/4 signaling has critical functions in cardiac development, including trabeculation and
formation of the conduction system.88–90,236 While previous studies have explored the role of
ErbB2/4 signaling in hPSC-CM differentiation,91,237 it remained unclear whether hPSC-CMs can
recapitulate the cardiotoxic effects of ErbB2 inhibition via trastuzumab exposure. Here we
demonstrate that, while functionally immature, iPS-CMs can recapitulate the cardioprotective
effects of ErbB2/4 signaling and the cardiotoxic effects of ErbB2 inhibition. Without the addition
of NRG-1 or HB-EGF to activate the ErbB2/4 pathway, we were not able to detect trastuzumab54

related cardiotoxicity. This result differs from two recent studies that observed change in cell
impedance and gene expression when hPSC-CMs were exposed to trastuzumab without the
addition of NRG-1 or HB-EGF.99,238 Interestingly, both studies used a commercially available
source of iPS-CMs and a proprietary maintenance medium, which may contain growth factors
that activate the ErbB2/4 pathway. The proprietary medium also contains animal-derived serum,
which has inherent variability between lots and can mask the effects of drugs.147,239 While we
utilized a serum-free growth medium, it is important to develop a chemically-defined medium
that contains growth factors appropriate for the cardiac microenvironment in order to improve
the relevance of iPS-CMs for drug screening applications.
While NRG-1 is widely known as the activating ligand of the ErbB2/4 pathway, we identify HBEGF as having a similar pattern of activation that results in cardioprotective effects against
doxorubicin. The addition of both NRG-1 and HB-EGF did not confer additive cardioprotective
effects, suggesting that both ligands activate ErbB2/4 signaling that is saturated by the addition
of NRG-1 alone at the tested concentrations. Therapeutic use of recombinant NRG-1 has been
extensively explored in animal models, showing improved cardiac function in disease models
such as myocardial infarction and doxorubicin-induced cardiomyopathy.240 Clinical trials have
also shown promising data on treating chronic heart failure patients using recombinant NRG1.241,242 HB-EGF has been shown to be critical in cardiac development and homeostasis in mice
through ErbB2/4 activation,243 but its potential therapeutic use in treating cardiovascular disease
has remained largely unexplored.244 While the cardioprotective effects of HB-EGF was less
pronounced compared to NRG-1 in our study, the clinical potential of HB-EGF warrants further
investigation.
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Trastuzumab has clinically been shown to induce cardiotoxic side effects including reduction in
the left ventricular ejection fraction (LVEF) and increases in the serum cardiac troponin I (cTnI)
concentration, suggesting ErbB2 inhibition directly affects cardiomyocyte viability.222,224 Loss of
cardiomyocytes is largely irreversible in the adult heart, and a recent study showed that
treatments using trastuzumab (with or without doxorubicin) resulted in reduced LVEF that does
not recover back to baseline after 5 years.223 On the other hand, we observed that the addition of
doxorubicin was necessary to detect trastuzumab-related cardiotoxicity using iPS-CMs. The
finding supports the existing theory that trastuzumab potentiates pre-existing cardiac stress
(drug-induced or otherwise) by inhibiting the cardioprotective effects of ErbB2/4 signaling.245–247
Mice with cardiac deletion of ErbB2 led to increased susceptibility to anthracycline-induced
cardiomyocyte death, suggesting that the physiological functions of ErbB2/4 signaling are
critical in preventing the progression of cardiac injury.225,248 No overt phenotype initially appears
in these mice, consistent with our finding that ErbB2 inhibition on its own does not induce acute
cardiotoxic effects.
Other potential mechanisms of trastuzumab-related cardiotoxicity have been proposed.
Trastuzumab has been shown to induce antibody-dependent cell-mediated cytotoxicity by natural
killer cells on Her2+ tumors,249 a process by which cardiomyocytes may be similarly affected.
Wilkinson et al.250 recently showed that human cardiac microvascular endothelial cells also
express ErbB2 and that their permeability is affected by exposure to trastuzumab. While we did
not observe any loss of EC viability through exposure to trastuzumab (data not shown), the
increased permeability may be a contributing factor to the clinically observed cardiotoxicity by
promoting higher transport and accumulation of doxorubicin into the heart. Barth et al.251
demonstrated that trastuzumab reduces the angiogenic capacity of human cardiosphere-derived
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cells in vitro, suggesting that trastuzumab exposure may affect the vascular response to stress in
the cardiac environment. Kirabo et al.252 recently showed that human cardiac ventricular
fibroblasts also respond to NRG-1 signaling, promoting the secretion of pro-reparative factors.
While we demonstrated that a simple co-culture system of iPS-CMs and ECs recapitulate
features of trastuzumab-related cardiotoxicity, it does not fully resolve all the potential
mechanisms of toxicity. With recent advancements in creating complex tissues and
microphysiological systems in vitro,253,254 future studies should aim to utilize multicellular
screening platforms to better model trastuzumab-related cardiotoxicity. Such platforms can be
leveraged during drug development to identify modes of cardiotoxicity that may be otherwise
missed using a cardiomyocyte mono-culture platform.
One limitation in our study is that we utilized a single iPSC line. Recent studies have
demonstrated that clinically-relevant cardiotoxicity of doxorubicin and sotalol can be predicted
using iPS-CMs differentiated from patient-derived iPSCs.208,215 Much like doxorubicin, not every
patient treated using trastuzumab shows clinical symptoms of cardiac dysfunction.255 It remains
to be seen if trastuzumab-related cardiotoxicity is a phenotype that is similarly dependent on the
genetic background of the patient and can be recapitulated using patient-derived iPS-CMs. Such
patient-specific models can be utilized to further our mechanistic understanding of trastuzumabrelated cardiotoxicity and aid in the development of therapeutic targets to more effectively
combat trastuzumab-related cardiotoxicity.
Another limitation in our study was the use of LDH release as the readout of cardiotoxicity. LDH
release is a clinically-relevant readout for cardiac injury but lacks specificity.256 We observed
that in the CM-EC co-culture platform, the ECs contributed a non-negligible amount of LDH,
which resulted in decreased sensitivity in detecting LDH release by the cardiomyocytes. While
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more costly and time-consuming, cardiomyocyte-specific markers of toxicity, such as cTnI and
cTnT release, can be utilized in the future for improved sensitivity and specificity in
cardiotoxicity screening.
In conclusion, we demonstrate that iPS-CMs recapitulate the cardioprotective effects of ErbB2/4
signaling and the cardiotoxic effects of ErbB2 inhibition by trastuzumab. We also establish a
simple and high-throughput CM-EC co-culture platform that recapitulates physiological
crosstalk between the two cell types including activation of ErbB2/4 signaling via EC-secreted
NRG-1. Further advancements in our ability to model the human cardiac microenvironment in
vitro will be critical in broadening our understanding of trastuzumab-related cardiotoxicity.

Chapter Authors
Yosuke Kurokawa, Michael R. Shang, Rose T. Yin, Steven C. George
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Chapter 5: Human Induced Pluripotent Stem Cell-Derived
Endothelial Cells for Three-Dimensional
Microphysiological Systems
5.1

Introduction

Nearly every tissue within the human body relies on vasculature for delivery of nutrients and
oxygen and removal of waste. In addition, the endothelial cells (EC) that line the vasculature
play critical roles in organ development, homeostasis, and disease progression.257–259 The
burgeoning field of microphysiological systems (MPS, or “organ-on-a-chip”) seeks to create
human tissue mimics at the micron to millimeter scale. These model systems have important
applications in the areas of in vitro pharmacokinetic modeling, drug toxicity, and drug efficacy.
The incorporation of dynamic and functional vascular networks into microphysiological systems
remains a priority, as it significantly advances the physiological relevance of these
systems.253,260–262 A variety of methods have been developed for creating 3D vasculature in
vitro,145,263,264 but we and others have focused on utilizing the native vasculogenic program of
endothelial cells to spontaneously form robust and perfusable vascular networks in microfluidic
devices.230,265–271 Such methods are amenable to including other functional cells types (e.g.,
hepatocytes, cardiomyocytes) to create complex, vascularized tissues that may be used for drug
screening and mechanistic studies.272–275
While efforts in the field have mostly revolved around the use of primary cells, there has been
growing interest in using human pluripotent stem cells (hPSC) as the source of endothelial cells
to create vessel networks. Employing a single stem cell line to derive endothelial cells has
several important advantages. First, concerns over donor-to-donor variability in primary cells
are ameliorated. Second, advances in gene editing (e.g. CRISPR) have facilitated the creation of
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stem cell lines that have useful reporters or modified functions for mechanistic studies.276
Finally, the use of human induced pluripotent stem cells (hiPSC) offers the potential to perform
disease-specific and patient-specific drug screening in vitro.253,277–280 Future applications may
also include using iPSC-derived endothelial cells (iPS-EC) as an autologous cell source for
regenerative medicine.
Several differentiation protocols now exist to create endothelial cells from hPSCs, usually
defined by the expression of definitive endothelial markers such as platelet-endothelial cell
adhesion molecule-1 (PECAM1, or CD31), vascular endothelial (VE)-cadherin (CD144),
endothelial nitric oxide synthase (eNOS), and von Willebrand factor (vWF).281–283 However,
studies that investigate their potential uses in microphysiological systems have been limited.
Belair et al.271 recently showed promising results using iPS-ECs for various in vitro assays that
demonstrate their physiological functions. In particular, they demonstrate the key roles of VEGF
and FGF signaling in sprouting angiogenesis of iPS-ECs. Most previous works have used
primary cell sources such as human umbilical vein endothelial cells (HUVEC) and endothelial
colony forming cell-derived endothelial cells (ECFC-EC), with ECFC-EC being considered the
desired cell source due to their high proliferative capacity and vasculogenic potential.284 It is of
great interest in the field to further understand how iPS-ECs perform in these platforms, thus
providing an important alternative to primary endothelial cells.
Herein we investigate the vasculogenic potential of iPS-ECs derived from an mCherry-VECadherin fusion protein reporter iPSC line. The cells demonstrate physiological functions of
endothelial cells, display a predominantly venous phenotype, respond to shear stress, and form
perfusable vascular networks within 3D microfluidic devices. We also demonstrate drug
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screening capabilities of the platform by observing changes in the vasculature in response to
small molecule inhibitors.

5.2

Materials and Methods

5.2.1 Cell culture
Two human iPSC lines were used in the experiments: WTC11 (gifted by Dr. Bruce Conklin,
Gladstone Institutes) and C2A (gifted by Dr. Gordana Vunjak-Novakovic, Columbia University).
The iPSC were cultured as described previously,232 with modifications. Briefly, the cells were
grown on 6-well plates coated with growth factor reduced Matrigel (Corning) in Essential 8 (E8)
Medium (Thermo Scientific) with daily media replacement. The cells were passaged at 80%
confluence using StemPro Accutase (Life Technologies) and seeded on Matrigel-coated plates in
E8 medium containing 10 µM Y-27632 (LC Laboratories), a Rho-associated protein kinase
(ROCK) inhibitor. All cells were cultured at 37 °C and 5 % CO2.
Human umbilical arterial endothelial cells (HUAEC), human umbilical venous endothelial cells
(HUVEC), and human dermal lymphatic endothelial cells (HDLEC) were purchased from
PromoCell and cultured according to manufacturer protocols. Endothelial colony forming cellderived EC (ECFC-EC) were isolated and cultured as described previously.230 Normal human
lung fibroblasts (NHLF) were purchased from Lonza and cultured according to manufacturer
protocols. The cells were used between passages 3-6.

5.2.2 CDH5-mCherry iPSC line
The CDH5-mCherry tagged cell line was generated from the GCaMP6-WTC11 human iPSC
line229 by the Genome Engineering and iPSC Center (GEiC), Washington University in St.
Louis. The GCaMP6-WTC11 line constitutively expresses GCaMP6 and can thus be used to
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report changes in intracellular calcium. Approximately 2 × 106 WTC11 iPSCs were resuspended
in P3 primary buffer and electroporated using a 4D-Nucleofector (Lonza) with 1.5 μg of CDH5mCherry donor plasmid (GeneArt), 1 μg gRNA (MS232.CDH5.g11 targets 5’taggcggccgaggtcactc tgg-3’ near the CDH5 stop codon) and 1.5 μg Cas9 vectors using
nucleofection program CA-137. Following nucleofection, cells were single-cell sorted and
screened with PCRs using primer sets specific to genomic and donor plasmid regions. The
overall nucleofection efficiency was 50-60% based on the expression of a co-delivered GFP
construct. CDH5-mCherry tagged region of final clones was sequence-confirmed using Sanger
sequencing.

5.2.3 Derivation and isolation of iPS-EC
The iPS-EC were differentiated following a previously established protocol (Fig. 5.1A).285
Briefly, ~80% confluent iPSC were split 1:4 onto Matrigel-coated tissue culture flasks as
described above (Day 0). Between Day 0 and Day 2 of differentiation, the cells were cultured in
E8BA medium, which consisted of E8 medium supplemented with 5 ng/ml BMP4 (R&D) and 25
ng/ml Activin A (PeproTech), with daily medium replacement. On Day 0 of differentiation, 10
µM Y-27632 was added to the E8BA medium. Between Day 2 and Day 6 of differentiation, the
cells were cultured in E7BVi medium, which consisted of Essential 6 (E6) Medium
supplemented with 100 ng/ml FGF2 (PeproTech), 10 ng/ml BMP4, 50 ng/ml VEGF-A
(PeproTech), and 5 µM TGF-β inhibitor SB431542 (STEMCELL Technologies), with daily
medium replacement. On Day 6, the cells were passaged using TrypLE (Life Technologies) and
sorted using CD31 Microbead Kit (Miltenyi Biotec) and EasySep™ Magnet (STEMCELL
Technologies) following manufacturer protocols. After purification, the CD31+ cells were
cultured on tissue culture flasks coated with human fibronectin (1 µg/cm2, Millipore) in E7V
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medium (E6 + 100 ng/ml FGF2 + 50 ng/ml VEGF-A). The cells were passaged on Day 8 using
TrypLE and frozen in CryoStor10 (STEMCELL Technologies) at 1x106 cells/ml. All
experiments were performed using cells between Day 10-18 differentiation.

5.2.4 Flow cytometry
Cells were passaged using TrypLE and fixed in Fixation Buffer (BioLegend) for 20 minutes. The
cells were washed in PBS and stained in Cell Staining Buffer (BioLegend) with CD31 (Dako),
CD90 (STEMCELL Technologies), or mouse IgG isotype control (Dako) for 30 minutes at room
temperature, followed by secondary antibody staining using goat anti-mouse IgG (H+L) Alexa
Fluor 647 (Invitrogen). The cells were also stained using preconjugated antibodies FITC-CD45
(BioLegend), PE-CD133 (Miltenyi Biotec), APC-CD34 (BioLegend), or a corresponding
preconjugated isotype control (BioLegend) in Cell Staining Buffer for 30 minutes at room
temperature. The samples were read using the Guava easyCyte Flow Cytometer (Millipore) with
a default number of events set at 5,000 and analyzed using FlowJo.

5.2.5 Immunofluorescent staining
Cells were fixed in 4% paraformaldehyde or 10% neutral buffered formalin for 10 minutes.
Permeabilization was performed using 0.1% Triton-X in PBS for 10 minutes. The cells were
blocked in 10% goat serum for 20 minutes. The cells were stained using antibodies for CD31
(Dako), VE-cadherin (R&D), von WIllebrand Factor (Abcam), eNOS (BD Biosciences), LYVE1 (Abcam), Podoplanin (BioLegend), PROX1 (Abcam), or laminin (Abcam) in PBS with 2%
bovine serum albumin (BSA, Sigma-Aldrich) for 60 minutes. Mouse IgG isotype control and
rabbit IgG isotype control (Abcam) were used as negative controls. After washing 3 times in
PBS, secondary antibodies Alexa Fluor 488 and Alexa Fluor 594 (Invitrogen) were used in PBS
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with 2% BSA for 45 minutes or overnight at 4 ˚C. After washing 3 times in PBS, nuclei were
stained using 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, Thermo Scientific) for 5
minutes. For staining microfluidic devices, all staining steps were performed overnight at 4 ˚C.
The cells were imaged using the IX83 inverted microscope or FV3000 confocal microscope
(Olympus).

5.2.6 Quantitative real-time PCR
RNA was isolated using RNeasy Plus Mini (QIAGEN) following manufacturer protocols. RNA
concentration was measured using NanoDrop 2000 (Thermo Scientific), and cDNA was
produced using High Capacity RNA-to-cDNA kit (Life Technologies). TaqMan Universal
Master Mix II and TaqMan Gene Expression Assays (Life Technologies) were used to assess
gene expression (Table S1). The qPCR reactions were performed using the CFX96 Real-Time
PCR Detection System (Bio-Rad). All reactions were performed in duplicate using 18S as an
endogenous control gene and analyzed using the comparative Ct method,233 normalizing the
expression level to ECFC-EC using the formula 2-ΔΔCt , where ΔΔCt is described as
[(Ct gene of interest – Ct 18S)sample of interest - (Ct gene of interest – Ct 18S)ECFC-EC]. The natural log of the ratio
of ephrinB2 and EphB4 expression was used to represent arterial versus venous phenotype, as
previously described.286

5.2.7 Tube formation assay
Undiluted Matrigel was used to coat the bottom of a 96-well plate and polymerized for 1 hour at
37 ˚C. Cells were seeded in EGM-2 with 50 ng/ml VEGF-A at 1x104 cells/well. The formation
of tubes was observed over a 72-hour period under a light microscope, and the total tube length
was calculated using ImageJ.
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5.2.8 Permeability assay
Fibronectin was coated on 12-well Transwell® inserts (Corning) with 0.4 µm membrane pore
size and incubated for 1 hour at 37 ˚C. Cells were seeded in EGM-2 with 25 ng/ml VEGF-A at
1.5x105 cells/well and cultured for 3 days with daily medium change. The luminal (top) chamber
was loaded with EGM-2 containing 0.1 mg/ml 70 kDa FITC-dextran, which was allowed to
diffuse through the cell monolayer into the abluminal (bottom) chamber. The abluminal chamber
was loaded with EGM-2 containing 0.1 mg/ml 70 kDa Texas Red-dextran to prevent osmotic
pressure formation. Medium volumes of 0.5 and 1.5 ml in the luminal and abluminal chamber,
respectively, were used to create equal hydrostatic pressures. After 2 hours, the amount of FITCdextran in the abluminal chamber was measured using the Infinite 200 PRO microplate reader
(Tecan), using a standard curve to interpolate the dextran concentration. The permeability of the
system (membrane plus cells) was estimated by using the equation Ps = (CA VA )⁄(tSCL ), where
CA and CL are the concentrations of the FITC-dextran in the abluminal and luminal chamber,
respectively; VA is the abluminal chamber volume, t is the time, and S is the surface area of the
membrane, as previously performed.287,288 The permeability of the cells was calculated using the
equation 1⁄Pcells = 1⁄Ps - 1⁄Pm , where Pm is the permeability of the membrane only.

5.2.9 mCherry-VE-cadherin response to thrombin
A monolayer of CDH5-iPS-ECs were grown to confluence over 48 hours. At the start of the
imaging, thrombin was added to the media (3 U/ml final concentration). Images were taken at 3
minute intervals for 45 minutes.
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5.2.10 Microfluidic device fabrication and culture
The microfluidic device were fabricated using standard soft lithography and replica molding
techniques, as described previously.230,275,289 The devices were cast of polydimethylsiloxane
(PDMS), plasma bonded onto glass slides, and sterilized before cell loading. For shear stress
experiments, the devices were coated with fibronectin for 1 hour at 37 ˚C before introducing the
cells at 2x107 cells/ml in a total volume of 2 µl. The cells were incubated for 2 hours at 37 ˚C
before feeding with E7V medium to flush out unattached cells. For the 3D vasculogenesis
assays, the devices were loaded through the side loading channel with 1x107 iPS-EC/ml and
5x106 NHLF/ml in 10 mg/ml fibrinogen (Sigma-Aldrich) and 0.25 U/ml aprotinin (SigmaAldrich) in 7.5 µl volume mixed with 0.9 µl of thrombin (3 U/ml final concentration, SigmaAldrich). The fibrin gel was polymerized for 15 minutes at 37 ˚C before coating the fluidic lines
with fibronectin (100 µg/ml). The devices were incubated for an additional 15 minutes at 37 ˚C
before feeding with endothelial growth medium 2 (EGM-2, Lonza) containing 0.25 U/ml
aprotinin.

5.2.11

Shear stress response

The iPS-EC were cultured in the microfluidic device for 3 days with daily medium change
before exposure to shear stress. COMSOL Multiphysics® was used to model and calculate the
flow necessary to achieve the desired average shear stress at the bottom surface of the device.290
The flow was set using the PHD ULTRA™ syringe pump (Harvard Apparatus) and Tygon®
flexible plastic tubing (Saint-Gobain). The shear stress response of the cells was observed under
the microscope over the course of 20 hours using the mCherry-VE-Cadherin reporter. The cell
perimeter and area were measured using ImageJ and used to calculate the circularity of the cell
[4π*area/(perimeter2)].
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5.2.12

Vasculogenesis device analysis

The co-cultured iPS-EC and NHLF were imaged and fed with EGM-2 every 2 days, with
alternating interstitial flow directions using a 5 mm H2O hydrostatic pressure difference across
the tissue chambers. Where indicated, SB431542 or sunitinib was supplemented at
concentrations of 10 and 0.1 µM, respectively. The barrier function of the vasculature was tested
by introducing 70 kDa FITC dextran (Molecular Probes) or fluorescent 1 µm diameter
FluoSpheres® microspheres (Molecular Probes) through the media channel. The devices were
fixed for immunofluorescence on Day 14. For vessel area quantification, a region of interest
(ROI) was selected to outline the chamber using ImageJ (NIH). A Gaussian blur was applied to
reduce noise, then the image was thresholded to create a binary image. The erode function was
used to further reduce noise, and the area was measured within the ROI. For vessel length
quantification, segmented lines were manually traced over the vessels within the ROI. The ratio
of the vessel area and the vessel length was used to quantify the average vessel diameter. Each of
the 3 chambers within the microfluidic device was analyzed separately, and each experimental
condition consisted of at least 3 independent devices. The images were blinded for analysis.

5.2.13

Statistical analysis

All experiments were performed using at least 3 biological replicates. Significance was
calculated using one-way analysis of variance (ANOVA) in conjunction with Tukey’s multiple
comparison test, with p-values less than 0.05 considered statistically significant. For the shear
stress response, each time point was compared to the control (Time 0) using one-way ANOVA in
conjunction with Dunnett’s multiple comparison test. For the vessel analysis, two-way ANOVA
in conjunction with Sidak’s multiple comparison test was used. All results are reported as
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mean±SD. Data were compiled, analyzed, and graphed using Microsoft Excel and GraphPad
Prism 6.

5.3

Results

5.3.1 Physiological characterization of iPS-EC
The iPS-ECs were differentiated using a monolayer, serum-free differentiation protocol as
diagramed (Fig. 5.1A). Day 6 of differentiation yielded a cell population that was 47.1±14.5%
CD31+ (Fig. 5.1B-i) prior to magnetic sorting. Following magnetic sorting, the cell population

Figure 5.1: Differentiation, isolation, and basic characterization of the iPS-EC. (A) Schematic of the iPSEC differentiation protocol. The iPS-ECs were isolated using MACS for CD31 on Day 6. (B) The
differentiated cells were analyzed for CD31 expression by flow cytometry at Day 6 (i) before sorting, (ii)
after MACS sorting, and (iii) 12 days of culture after sorting. Blue = isotype control. The expression of
definitive endothelial markers was confirmed using immunofluorescence for (C) CD31, (D) VE-cadherin,
(E) vWF, and (F) eNOS. Scale bar: 50 µm.
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was purified to 94.8±2.9% CD31+ (Fig. 5.1B-ii). The cells were then grown on fibronectincoated tissue culture plastic, and an additional 12 days of culture further enriched for iPS-ECs,
yielding 98.3±0.9% CD31+ cells (Fig. 5.1B-iii). The sorted iPS-EC population also expressed the
endothelial progenitor cell (EPC) marker CD34 (82.4±9.6%), while a small subpopulation
stained positively for another EPC marker CD133 (5.90±1.11%) (Fig. A3.1A, A3.1B). The cells
did not express the hematopoietic marker CD45 (0.87±0.19%) while staining positively for the
mesenchymal marker CD90 (93.2±3.39%), which has previously been shown to be expressed in
EPCs (Fig. A3.1C, A3.1D).291,292 The resulting cells demonstrated a “cobblestone” morphology
characteristic of primary endothelial cells including HUAEC, HUVEC, HDLEC, and ECFC-EC
(Fig. A3.2A). These cells also had protein expression characteristic of endothelial cells,
including expression of CD31 and VE-cadherin that predominantly co-localized at cell junctions
(Fig. 5.1C, 1D) and cytoplasmic expression of vWF and eNOS (Fig. 5.1E, 1F). ECFC-ECs were
used as a positive control, while isotype IgG antibodies were used as negative controls (Fig.
A3.2B, A3.2C). Successful differentiation and isolation was achieved using 2 different human
iPSC lines (Fig. A3.2D). The iPS-ECs thawed from Day 8 of differentiation underwent ~7-fold
increase in cell number before undergoing senescence (Fig. A3.2E). Culturing the iPS-EC in
EGM-2 instead of the E7V medium resulted in observable dedifferentiation of the iPS-EC into
cells of stromal- or smooth muscle-like morphology (Fig. A3.2F).

5.3.2 Phenotypic characterization of iPS-ECs
In addition to the definitive endothelial markers, we investigated the expression of markers that
define arterial, venous, and lymphatic endothelial phenotype. We specifically measured the ratio
of the expression of the putative arterial and venous markers (ephrinB2 and EphB4,
respectively).293,294 The results were compared to primary human endothelial cells of known
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phenotype, and normalized to ECFC-ECs as the progenitor endothelial cell control. As expected,
the HUAECs had a more arterial-like phenotype compared to ECFC-ECs (higher ratio of
ephrinB2 to EphB4), while HUVECs and HDLECs had a more venous-like phenotype (Fig.
5.2A). The iPS-ECs also demonstrated a strong venous phenotype compared to ECFC-ECs (Fig.
5.2A). To distinguish between venous and lymphatic endothelial phenotype, we investigated the

Figure 5.2: Phenotype characterization of iPS-EC. (A) The ratio of ephrinB2 to EphB4 expression levels
measured by qPCR. The expression levels are normalized to ECFC-EC, with values greater than 0
indicating a more arterial phenotype than ECFC-EC. HUVEC, HDLEC, and iPS-EC demonstrate a more
venous phenotype than ECFC-EC. *p<0.05 compared to iPS-EC. (B) Expression levels of lymphatic
markers measured by qPCR, normalized to ECFC-EC. *p<0.05 compared to iPS-EC. (C) Expression of
lymphatic markers confirmed by immunofluorescence. The HDLEC stain positively for all 3 markers
while the iPS-EC only stain positively for LYVE-1. Blue = DAPI. Scale bar: 50 µm.
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expression of 3 different lymphatic endothelial markers: lymphatic vessel endothelial hyaluronan
receptor-1 (LYVE-1), Prospero homeobox protein 1 (PROX1), and podoplanin (PDPN). As
expected, the HDLECs showed positive expression of all 3 markers (Fig. 5.2B). The iPS-ECs
showed low expression of PDPN and PROX1, but showed high expression of LYVE-1 (Fig.
5.2B). A similar expression pattern was observed for the ECFC-ECs (Fig. 5.2B). The expression
pattern of the lymphatic markers for iPS-ECs and HDLECs was confirmed using
immunofluorescence (Fig. 5.2C).

5.3.3 CDH5-mCherry iPSC line
Using CRISPR/Cas9, we established a mCherry-VE-cadherin reporter iPSC line. The iPS-ECs
derived from the CDH5-mCherry iPSC line (CDH5-iPS-EC) demonstrated robust mCherry
signal that co-localized to the cell junctions, as well as an accumulation of the signal near the cell
nucleus (Fig. 5.3A). Since VE-cadherin is involved in maintaining endothelial barrier
function,295 we investigated whether the fusion protein impacted the permeability of the CDH5iPS-EC monolayer. Using a Transwell permeability assay, we observed no statistically
significant difference in the diffusion of 70 kDa dextran between the CDH5-iPS-ECs, iPS-ECs,
and ECFC-ECs (Fig. 5.3B). All 3 EC types demonstrated significantly lower permeability of 70
kDa dextran compared to fibroblasts, with permeability values comparable to previous studies
using primary vascular endothelial cells (4.73x10-6 ± 0.85x10-6cm/s for CDH5-iPS-EC) (Fig.
5.3B).287,296 We also studied the ability of the CDH5-iPS-ECs to form tube-like structures on
Matrigel (Fig. 5.3C). Again, we observed no statistically significant difference between the
CDH5-iPS-ECs, iPS-ECs, and ECFC-ECs (Fig. 5.3D). In addition, we tested the physiological
response to the CDH5-iPS-EC to thrombin, which induces EC retraction through the
redistribution of VE-cadherin.297 Time-lapse imaging of the CDH5-iPS-ECs showed dissociation
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Figure 5.3: The use of CDH5-mCherry iPSC-derived EC (CDH5-iPS-EC). (A) The CDH5-iPS-ECs
demonstrate mCherry signal that localizes to cell junctions. (B) The permeability measured by the
diffusion of 70 kDa dextran across a cell monolayer. The permeability of CDH5-iPS-EC monolayer is
unchanged compared to iPS-EC as well as ECFC-EC. *p<0.05 compared to CDH5-iPS-EC. (C)
Representative image of Matrigel tube formation assay for CDH5-iPS-EC. (D) The total tube length
normalized to ECFC-EC. No significant differences were observed across the 3 EC types. (E) CDH5-iPSEC response to thrombin. The mCherry-VE-cadherin disaggregate from cell junctions, resulting in the
formation of intercellular gaps (indicated by white arrows). (F) The CDH5-iPS-ECs are used to image the
response to shear stress in real time. The cells demonstrate a more elongated morphology over time. (G)
The circularity of the CDH5-iPS-EC in response to shear stress is calculated over time. *p<0.05
compared to time 0. Line indicates a one phase decay fit with 95% confidence band. Scale bar: 50 µm
(A,E,F), 500 µm (C).
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of the mCherry-VE-cadherin signal at cell junctions in response to thrombin, resulting in EC
retraction and formation of intercellular gaps (Fig. 5.3E).

5.3.4 iPS-EC response to shear stress
Using the CDH5-iPS-ECs, we investigated the cellular response to an applied shear stress. We
utilized a microfluidic device that consisted of microfluidic lines 10 mm in length with cross
sectional dimensions of 800 and 100 µm in width and height, respectively. Using finite element
modeling to determine the fluid shear stress, we set the fluid flow within the line to produce an
average shear stress of 4 dynes/cm2 (Fig. A3.3). The cells were observed using time-lapse
imaging of the mCherry-VE-cadherin signal, and morphological changes were observed over the
course of 20 hours (Fig. 5.3E). Using circularity as a morphological index, we observed
significant elongation of the cells in response to shear stress (Fig. 5.3F).

5.3.5 3D iPS-EC vascular networks
We next investigated the ability of the CDH5-iPS-ECs to form 3D vascular networks by coculturing them with fibroblasts in microfluidic devices (Fig. 5.4A). Using the mCherry-VEcadherin signal to track vessel formation, we observed the development of a robust vessel
network over the course of 14 days (Fig. 5.4B, quantitative analysis in Fig. 5.5). The iPS-ECs
undergo vacuole formation and aggregate into tube-like structures in the first 48 hours, as
previously observed using primary ECs (Fig. A3.4A).298 The microvessel network connected to
the top and bottom microfluidic lines (Fig. 5.4C), enabling the flow of media through the
vascular networks without leakage into the surrounding tissue space. The vessels have a
complete lumen as confirmed by staining for CD31 and imaging using confocal microscopy (Fig.
5.4D). Co-staining for laminin, a basement membrane protein, we observed the localization of
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Figure 5.4: 3D culture of iPS-EC in microfluidic devices. (A) Schematic illustration of the microfluidic
device. The cell suspension in fibrin is loaded into the tissue chamber region, while media is delivered
through the top and bottom fluidic lines. (B) Representative images of the vessel network formation by
CDH5-iPS-EC tracked over a period of 14 days. (C) The vessel anastomoses to the top fluidic line as
indicated by the continuous CDH5-iPS-EC lining around the opening of the tissue chamber.
(legend continued on next page)
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Figure 5.4 (Cont.): (D) The microvessels demonstrate a patent lumen as confirmed by confocal
microscopy. The dashed box region: (E) the iPS-ECs deposit laminin as a part of the basement
membrane. (F) The vessel network effectively retains 70 kDa dextran introduced through the top fluidic
line. (G) 1 µm bead (red) is captured flowing through the vessel. Scale bar: 200 µm (B,F), 50 µm (C), 100
µm (D), 25 µm (E,G).

laminin on the outer wall of the microvessels as outlined by CD31 (Fig. 5.4E). The vascular
network demonstrates a physiological barrier function, as they effectively retain fluorescently
labeled 70 kDa dextran (Fig. 5.4F). Furthermore, we were able to flow 1 µm beads through the
vessels (Fig. 5.4G).

5.3.6 Supplementation of small molecule TGF-β inhibitor
Since TGF-β inhibition has an established effect of enhancing iPS-EC proliferation in monolayer
culture,299 we explored whether TGF-β inhibition also leads to improved vessel network
formation. A small molecule TGF-β inhibitor (SB431542) was supplemented into the growth
medium, and the vessel formation was compared to the control condition (Fig. 5.5A). The
addition of SB431542 resulted in a significant increase in vessel length (26-49%) at all measured
time points (Day 6, 10, 14) (Fig. 5.5B). The increase in vessel area (23-57%) was statistically
significant for Day 6 and 10, and showed a strong positive trend for Day 14 (p=0.12) (Fig. 5.5C).
No statistically significant difference in the average vessel diameter was observed at all 3 time
points (Fig. 5.5D).

5.3.7 Vessel response to anti-angiogenic drug
To further demonstrate the utility of the platform, we investigated the effects of the antiangiogenic drug sunitinib. Sunitinib is a multitargeted tyrosine kinase inhibitor used for cancer
treatment due to its anti-angiogenic and anti-tumor activities.300,301 On Day 6 of culture, sunitinib
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Figure 5.5: Response of iPS-EC
vasculature to small molecule
inhibitors. (A) Representative CDH5iPS-EC vessel networks developed at
day 14 with or without the
supplementation of SB431542 in the
growth medium. The addition of
SB432542 significantly increased (B)
the total vessel length and (C) the total
vessel area coverage within the tissue
chamber. *p<0.05 compared to control
at the given time point. (D) The
average vessel diameter is not
significantly affected by the addition of
SB431542. (E) The total vessel area
within the tissue chamber decrease in
response to sunitinib treatment.
*p<0.05 comparing control versus
sunitinib-treated condition at the given
time point.

was added to the medium at 100 nM, and we observed statistically significant reduction in the
total vessel area compared to control (Fig. 5.5E).

5.4

Discussion

In this study, we characterized critical physiological functions of iPS-ECs using 2D and 3D in
vitro cultures. The iPS-ECs demonstrated the expression of several definitive endothelial cell
markers and maintained this expression pattern even after 12 days of culture in a serum-free
medium. We established a novel CDH5-iPS-EC line expressing the mCherry-VE-cadherin fusion
protein, which was used to perform live cell imaging at various time points over the course of a
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single experiment. The gene expression pattern of the iPS-ECs suggests a venous-like
endothelial phenotype compared to ECFC-ECs. The iPS-EC monolayer demonstrates
physiological barrier functions, a shear stress response, and the ability to form vessel structures
when cultured on Matrigel. In 3D, the iPS-EC are capable of undergoing vasculogenic and
angiogenic processes to form robust, perfusable vascular networks. Finally, we demonstrate that
the iPS-EC vascular networks are responsive to small molecule inhibitors that have angiogenic
or anti-angiogenic effects. Thus, the CDH5-iPS-EC line provides a convenient yet robust model
that is consistent with the physiological characteristics of primary ECs. Based on their ability to
form 3D perfused vascular networks, we believe iPS-ECs have the potential to be used in a wide
range of in vitro and in vivo tissue engineering applications.
The iPS-EC differentiation protocol utilized here has several advantages compared to several
previously established differentiation protocols. The differentiation does not vary in technique
from the standard monolayer, feeder-free culture of hPSC, requiring no additional steps for
embryoid body formation or suspension culture. The differentiation and maintenance media are
serum-free, which minimizes the variability in the differentiation protocol. Bao et al.302 recently
reported the successful differentiation of human iPS-ECs using chemically-defined, albumin-free
media and xenogen-free substrate (Synthemax vitronectin). While their reported differentiation
efficiency is lower than achieved here (~30% vs. ~45%), further advancements in chemicallydefined differentiation protocols could further improve reproducibility and translational
applications.
Additionally, selecting an appropriate iPS-EC differentiation strategy requires careful
consideration of the intended application and function of the tissue. Whereas the iPS-ECs
derived here demonstrated a predominantly venous phenotype, previous studies have reported a
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more arterial phenotype, especially when cultured in high concentrations of VEGF-A.303–305
Other groups have reported an indeterminate phenotype, which may be an indication of the
immaturity of the iPS-ECs.286,306 Differences are likely due to the distinct differentiation
protocols utilized by the different research groups, highlighting the sensitivity in differentiating
ECs from hPSCs and that further work is needed to better control this process. The expression of
LYVE-1 without the expression of other lymphatic markers is consistent with previous
findings.299,306 It has been shown that LYVE-1 expression is not limited to lymphatic ECs,307 and
the lack of expression of PROX1 and PDPN strongly suggests that the iPS-ECs in our study are
indeed more venous-like and not lymphatic. It remains to be seen how the phenotype-specific
functions of iPS-ECs will influence their potential applications in MPS. In addition to the basic
phenotype of the iPS-ECs, it will be critical to consider organ- and tissue-specific functions of
endothelial cells in order to further advance the capabilities of MPS to model the in vivo
microenvironment.258,282,308
We established a CDH5-mCherry human iPSC line that can be utilized to generate iPS-ECs
expressing an mCherry-VE-cadherin fusion protein. While we did not detect any dysregulation
in the CDH5-iPS-EC barrier function or response to thrombin, we observed mCherry signal
accumulation around the cell nucleus. We believe that this cytoplasmic mCherry signal is due to
VE-cadherin internalization, as VE-cadherin has known mechanisms of endocytosis in response
to signaling factors such as VEGF and thrombin.297,309 Indeed, some of the mCherry signal can
be observed entering the cytoplasm of the cell in response to thrombin. Similar observations of
signal accumulation were made in previous works using HUVECs that expressed fluorescentlylabeled VE-cadherin via lentiviral transduction.310,311 While efficient, lentiviral systems have
significant shortcomings, as the gene encoding the fusion protein is randomly inserted into the
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genome and the expression of the protein is forced through a promoter sequence. The CDH5mCherry iPSC line utilized CRISPR/Cas9 to specifically modify the CDH5 gene; thus, the
mCherry signal is only observed in cells that express VE-cadherin using the native promoter.
Further genetic modifications can be made on the CDH5-iPSC line to perform mechanistic
studies on VE-cadherin and its role in EC physiology and pathophysiology.
While the iPS-ECs formed 3D vessel networks within the microfluidic device, we utilized a
relatively high density of iPS-ECs (1x107 cells/ml) to achieve consistent vascular network
formation. We observed that the iPS-ECs loaded at the same concentration as previous
experiments using ECFC-ECs (5x106 cells/ml) resulted in fragmented vessel networks that did
not consistently form a continuous vessel network across the top and bottom fluidic lines (Fig.
A3.4B). In addition, we observed a large number of iPS-ECs within the device that did not
integrate into vessel networks. These data suggest that the iPS-ECs have a limited vasculogenic
potential compared to the ECFC-ECs, and that the iPS-EC population may include poorly
differentiated cells that have vasculogenic deficiencies. While the iPS-ECs express CD31,
additional markers may be necessary to select for a highly vasculogenic iPS-EC subpopulation.
For example, neuropilin-1 (NRP-1) is a marker that has been shown to select for a human iPSEC subpopulation that shows high proliferative capacity and robust vessel network formation in
vivo.277,312 Hu et al.313 recently reported that iPS-ECs differentiated from an iPSC line that
originates from ECs (as opposed to fibroblasts) have higher expression of EC markers,
suggesting that the cellular origin of the iPSC may also play a role in iPS-EC functionality.
Additional studies are necessary to investigate how to enrich for highly vasculogenic iPS-ECs.
The data also highlights the inability of the Matrigel tube formation assay to assess vasculogenic
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potential of ECs, as no significant difference between the ECFC-ECs and iPS-ECs were
detected.
Our investigations of the microvessels formed by the iPS-ECs demonstrate features of a mature
vasculature. The microvessels demonstrate a continuous basement membrane that stained
positively for laminin, a key ECM protein involved in vessel stabilization and maturation.314 This
is in contrast to the iPS-ECs cultured in a 2D monolayer where laminin staining is discontinuous
and localizes around the nucleus (Fig. A3.5), as similarly observed in a previous study.315 It is
also interesting to note that the iPS-ECs in the device were cultured using EGM-2 for 14 days, a
condition under which the iPS-ECs cultured in a 2D monolayer showed a propensity to
dedifferentiate into cells with a stromal phenotype. These data suggest that the 3D culture of the
iPS-ECs in the presence of fibroblasts can enhance the phenotypic commitment of the iPS-ECs.
Cytokines released by fibroblasts have been demonstrated as a critical component in the
formation of stable microvessels in vitro.266,316 Further studies are required to establish if these
cytokines enhance the differentiation and maturation of iPS-ECs.
We demonstrated that the iPS-EC vessel network formation can be improved by the addition of a
small molecule TGF-β inhibitor SB431542in the culture medium. SB431542 inhibits TGF-β
signaling by blocking activin-like kinase (ALK) receptors317 and is commonly used to enhance
EC differentiation and expansion.285,286,299,306,318 Using 2D tube formation assays, previous
studies have shown that the addition of SB431542 in the culture medium can enhance area of
coverage and total branch number of iPS-ECs.306,318 A similar response is observed in our 3D
vasculogenesis assay using iPS-ECs, as the addition of SB431542 results in significant increases
in both the total vessel area and the total vessel length. No significant increase in the average
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vessel diameter was observed, indicating that the increased branching of the vasculature leads to
the increased total vessel area.
In conclusion, this study advances the current understanding of iPS-ECs and their utility in
creating advanced MPS. The iPS-ECs demonstrate physiological functions in both 2D and 3D
culture, and can be manipulated to create robust microvascular networks in microfluidic devices.
By understanding the basic characteristics and behavior of iPS-ECs, the tissue engineering
community can make informed decisions on the integration of iPS-ECs in advancing MPS as
well as other tissue engineering platforms.
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Chapter 6: Challenges and Opportunities
Over the last 5 years, significant advancements have been made in the field of cardiac
microphysiological systems and its applicability for in vitro drug screening. Notwithstanding,
several key challenges still remain before researchers can fully realize the potential of human
iPSC-derived cardiovascular cells for drug screening applications.

6.1

Integration of Organ Systems

Integrating multiple organ systems has been a long-term goal of the Microphysiological Systems
Program.10 Such integrated platforms, termed “human-on-a-chip”, can provide information on a
compound of interest that is not possible to obtain using simpler in vitro platforms. For example,
the integration of a liver microphysiological model will be significant for understanding the
effects of the drug metabolites.319 Researchers also envision using an integrated platform to study
the pharmacokinetics of how a drug of interest will be distributed throughout the body.320 Such
an in vitro platform can complement computational models and animal studies to better predict
drug safety and efficacy in human patients. Such a system also has higher physiological
relevance by recapitulating the interaction between different organ systems, which may be
critical for understanding specific drug mechanisms.
Several critical challenges exist for creating integrated microphysiological platforms. One is the
choice of growth medium. Most commercially available growth media have been optimized for a
small subset of cell types, whereas a universal medium that can support the physiological
function of all the integrated organ systems is desirable.321 The scaling of the integrated organ
systems in terms of their physiological function must also be optimized so as to mimic the
human body.260 The technical challenges of connecting microfluidic systems with the proper
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fluidics to support the organ systems must also be addressed to increase throughput of such
platforms for drug screening applications.

6.2

Disease Modeling

The ability of microphysiological systems to recapitulate disease states will be critical for drug
development. In the field of cardiovascular disease modeling, significant progress has been made
using cardiomyocytes differentiated from patient-derived iPSCs carrying a disease-related
genetic mutation. Many monogenic diseases, such as dilated cardiomyopathy and long-QT
syndrome, can be recapitulated at the single cardiomyocyte level, and new molecular targets and
therapeutic options are being proposed using such disease models.322–324 However, more
complex diseases, such as atrial fibrillation and hypertension, are difficult to model due to the
unknown nature of all the contributing factors that cause the disease in patients. As more
advanced microphysiological systems develop, it may be possible to use these platforms to
mechanistically probe stimuli that induce the disease phenotype.
More advanced disease models also open the potential for phenotypic drug screening, which
focuses on identifying compounds that modulate the disease-linked phenotype. Phenotypic drug
screening was commonly performed in animal models before the popularization of target-based
drug screening, and has recently regained use in part due to advancements in disease models.325
One of the critical components to a phenotypic drug screening is a physiologically-relevant
model of the disease.326 Using such platforms, compounds of potentially novel mechanisms can
be identified that effectively correct the disease phenotype.
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6.3

Patient-Specific Drug Screening

The concept of patient-specific drug screening, also referred to as personalized medicine or
precision medicine, has gained significant traction over the past decade, as studies have shown
that many drugs have different responses in patients with different genetic backgrounds.327 The
ability to use multiple iPSC lines to represent a varied genetic background in patients holds a
strong potential for patient-specific drug screening to become a reality. Recent research findings
have proven the concept of personalized medicine to be effective in predicting cardiovascular
drug response. Burridge et al.215 demonstrated that iPS-CMs recapitulated doxorubicin-induced
cardiotoxicity at a patient-specific level: iPS-CMs from patients who displayed symptoms of
doxorubicin-induced cardiotoxicity had lower tolerance to doxorubicin in vitro. Matsa et al.328
demonstrated that reprogramming and differentiation of patient-derived cells into iPS-CMs
preserve the patient’s genetic background and that their transcriptomic profile can be used to
predict drug-induced cardiotoxicity. Stillitano et al.208 demonstrated that iPS-CMs accurately
predicts changes in electrophysiology induced by the drug sotalol, showing a good match to the
observed patient response.
Several challenges remain to realize the potential of patient-specific drug screening. The
associated cost of utilizing patient-specific models instead of a single model must be addressed.
While the potential benefits to the patients are immense, the personalized medicine approach
may not offer enough to pharmaceutical companies to offset the increased cost, especially for
rare-diseases that may only benefit a small subpopulation.329 It also remains to be seen if certain
diseases can be predicted at the patient-specific level. While genome-wide association studies
have helped identify common mutations that puts patients at risk for certain diseases, nonheritable diseases have no known genetic profile that predisposes a person to the disease.330 As
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alluded to in Chapter 4, it remains to be seen if trastuzumab-related cardiotoxicity can be
predicted at the patient-specific level. Since most of the work presented in this dissertation was
performed using human iPSC-derived cells, it is possible to add components of patient-specific
drug screening into the presented platforms. However, considerable progress in the science of
personalized medicine and cost reduction of the associated methods must be achieved before the
practice becomes a standard of care at the clinical level.

6.4

Conclusion

Microphysiological systems have the potential to resolve some of the critical issues in drug
development today. As we create more advanced models of the human body, we can improve
our understanding of human physiology and pathophysiology which in turn guides the drug
development process. The use of iPSCs open doors to disease- and patient-specific drug
screening applications, which have transformative potential in the pharmaceutical industry.
Strong interest and funding from academia, industry, and government agencies have been critical
for the rapid development of microphysiological systems, and continued support will be required
to realize commercial success of the technology. Many challenges remain, and it will be exciting
to see new research findings and technological breakthroughs address these challenges in the
future.
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Appendix

Figure A1.1: Parameters derived from the contractile profiles based on the 1st PCA of motion vectors.
(Left panel) Red indicates the contraction phase of an iPS-CM beat and has positive PCA values. The
blue indicates the subsequent relaxation phase of a beat and is designated by negative PCA values. (Right
panel) List of the 12 parameters that are extracted from the contractile profile.
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Figure A1.2: (A-C) Set 1 &2 of the longitudinal experiments had acquisitions taken at intervals of 30
minutes; while Set 3 had acquisitions taken at intervals of 9 minutes with exception of last time point
(time point was taken at 90 minutes instead). The results showed a similar decrease in CTD90, suggesting
that there is little to no recovery from photobleaching during the length of the experiment. While the
decrease is similar, the CTD90 values among each of the sets of microscope chamber slides used for the
longitudinal experiment decreased at different rates. (D-E) The calculated SR90 for all three sets removed
the decaying trend among acquisitions. (F-G) To control for the different initial CTD90 values, all
subsequent values were normalized to the starting values. The normalization still yielded decreasing
trends that differed among the sets. (J-L) The best-fit lines generated from the linear regression of the
normalized SR90 values were relatively uniform.
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Figure A1.3: Analysis of GCaMP6 data from longitudinal study. With the GCaMP6 method, no
significant changes in the (A) beating rate or (B) SR90 were detected at any of the time points (n = 13).

Figure A1.4: Analysis of GCaMP6 data from placebo study. During the length of the placebo
experiments, there was no observable change in the (A) beating rate or (B) SR90 using the GCaMP
analysis (n =18).
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Figure A2.1: Differentiation and isolation of iPS-CMs. (A) Schematic diagram of iPS-CM
differentiation and purification. The cells are passaged on Day 24 to be cryopreserved or
replated. (Δ) denotes one medium change. (B) Flow cytometry analysis of the resulting iPS-CM
population. The cells are stained for the expression of cTnT. (C) Immunofluorescence of the iPSCMs replated in a 96-well plate. Green = cTnT, blue = DAPI. Scale bar = 50 µm.
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Figure A2.2: Co-culture of iPS-CM and ECFC-EC at a ratio of 40,000:5,000 CM:EC in a 96-well plate.
Green = iPS-CM (GCaMP6), red = ECFC-EC (transduced). Scale bar = 250 µm.
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Figure A3.1: Flow cytometry analysis of iPS-ECs on Day 8. The magnetically sorted iPS-EC population
was checked for expression of (A) CD34, (B) CD133, (C) CD90, and (D) CD45. Blue = isotype control.
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Figure A3.2: Characterization of iPS-ECs. (A) Representative brightfield of primary and iPS-derived
endothelia cells. (B) ECFC-ECs were used as positive controls for staining for the endothelial cell
markers. Blue = DAPI. (C) Mouse and rabbit IgG isotype control antibodies were used as negative
controls for staining the iPS-ECs. (D) iPS-ECs differentiated from the C2A line, stained for CD31
expression. Blue = DAPI. (E) iPS-EC growth curve showing fold increase from Day 8 to Day 30 of
differentiation. (F) The iPS-ECs demonstrate a morphological change when cultured in EGM-2 instead of
E7V medium. Scale bar: 100 µm (A,F), 50 µm (B,C,D).
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Figure A3.3: COMSOL model of the microfluidic device for the shear stress experiments. (A) The
computer aided design (CAD) file used for the microfabrication of the device was imported into
COMSOL as an object geometry. (B) The shear stress of the cross-sectional region of the microfluidic
device. A near-constant shear stress is experienced across the bottom surface of the device.
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Figure A3.4: CDH5-iPS-EC vasculature formation in the microfluidic platform. (A) Within 48 hours
after loading the cells, the iPS-ECs undergo vacuole formation and aggregation into vessel-like structures.
(B) At Day 14, the lower cell density (5x106 cells/ml) loading results in fragmented vessels that do not
form a continuous vessel network across the fluidic lines.

Figure A3.5: Laminin staining of an iPS-EC monolayer. Blue = DAPI. Scale bar: 50 µm.
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